Cancer-associated antibody compositions and methods of use

Abstract

The disclosure herein relates to novel cancer-associated antibodies and antigen-binding fragments for diagnosing cancer or its metastasis. The disclosure herein relates to novel cancer-associated antibodies and antigen-binding fragments for treating cancer or its metastasis. The disclosure herein relates to novel chimeric antigen receptors or T cell receptor fusion proteins comprising one or more cancer-associated antigen binding domains that can be used to treat cancer.

Description

[0001] Cross-references

[0002] This application claims the benefit of U.S. Provisional Application No. 62 / 840,638, filed April 30, 2019, U.S. Provisional Application No. 62 / 840,640, filed April 30, 2019, U.S. Provisional Application No. 62 / 840,644, filed April 30, 2019, U.S. Provisional Application No. 62 / 840,648, filed April 30, 2019, U.S. Provisional Application No. 62 / 840,855, filed April 30, 2019, U.S. Provisional Application No. 62 / 840,858, filed April 30, 2019 U.S. Provisional Application No. 62 / 840,860, filed on April 30, 2019, U.S. Provisional Application No. 62 / 840,861, filed on April 30, 2019, U.S. Provisional Application No. 62 / 840,864, filed on April 30, 2019, U.S. Provisional Application No. 62 / 840,870, filed on April 30, 2019, U.S. Provisional Application No. 62 / 840,875, filed on April 30, 2019, U.S. Provisional Application No. 62 / 840,880, filed on April 30, 2019 U.S. Provisional Application No. 62 / 840893 filed on April 30, 2019, U.S. Provisional Application No. 62 / 840904 filed on April 30, 2019, U.S. Provisional Application No. 62 / 840909 filed on April 30, 2019, U.S. Provisional Application No. 62 / 840917 filed on April 30, 2019, U.S. Provisional Application No. 62 / 840938 filed on April 30, 2019, U.S. Provisional Application No. 62 / 840950 filed on April 30, 2019, U.S. Provisional Application No. 62 / 840969 filed on April 30, 2019 Provisional Application No. 62 / 840,957, U.S. Provisional Application No. 62 / 840,970 filed on April 30, 2019, U.S. Provisional Application No. 62 / 841,036 filed on April 30, 2019, U.S. Provisional Application No. 62 / 841,044 filed on April 30, 2019, U.S. Provisional Application No. 62 / 841,047 filed on April 30, 2019, and U.S. Provisional Application No. 62 / 841,049 filed on April 30, 2019; each of which is incorporated herein by reference in its entirety.

[0003] References to sequence listings

[0004] This application includes a sequence listing that has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. The ASCII copy was created on April 28, 2020, is named 54407_705_601_Sequence_Listing.txt, and is 4,053,188 bytes in size. Background Art

[0005] While the role of cytotoxic T cells in mediating anticancer immune responses is well established, the role of B cells is less well understood. In particular, the role of antibodies identified in cancer patients remains unclear: while some studies suggest that such antibodies may promote tumor progression, others report that they may stimulate antitumor immunity. Summary of the invention

[0006] In one aspect, the present invention provides an antibody or an antigen-binding fragment thereof, which comprises at least one of a variable heavy chain complementary determining region 1 (CDR-H1), CDR-H2 and CDR-H3, wherein: CDR-H1 comprises a reshaped polypeptide consensus sequence selected from any one of SEQ ID NOs: 543-813, CDR-H2 comprises a reshaped polypeptide consensus sequence selected from any one of SEQ ID NOs: 1085-1355, and CDR-H3 comprises a reshaped polypeptide consensus sequence selected from any one of SEQ ID NOs: 1627-1897.

[0007] In one aspect, the present invention provides an antibody or an antigen-binding fragment thereof, which comprises at least one of a variable light chain complementary determining region 1 (CDR-L1), CDR-L2 and CDR-L3, wherein: CDR-L1 comprises a reshaped polypeptide consensus sequence selected from any one of SEQ ID NOs: 814-1084, CDR-L2 comprises a reshaped polypeptide consensus sequence selected from any one of SEQ ID NOs: 1356-1626, and CDR-L3 comprises a reshaped polypeptide consensus sequence selected from any one of SEQ ID NOs: 1898-2168.

[0008] In one aspect, the present invention provides an antibody or antigen-binding fragment thereof, comprising: a variable heavy chain complementary determining region 1 (CDR-H1), CDR-H2 and CDR-H3, wherein: CDR-H1 comprises a restructured polypeptide consensus sequence selected from any one of SEQ ID NOs: 543-813, CDR-H2 comprises a restructured polypeptide consensus sequence selected from any one of SEQ ID NOs: 1085-1355, and CDR-H3 comprises a restructured polypeptide consensus sequence selected from any one of SEQ ID NOs: 1627-1897; and a variable light chain complementary determining region 1 (CDR-L1), CDR-L2 and CDR-L3, wherein: CDR-L1 comprises a restructured polypeptide consensus sequence selected from any one of SEQ ID NOs: 814-1084, CDR-L2 comprises a restructured polypeptide consensus sequence selected from any one of SEQ ID NOs: 1356-1626, and CDR-L3 comprises a restructured polypeptide consensus sequence selected from any one of SEQ ID NOs: 1898-2168.

[0009] In some embodiments, the antibody comprises IgG, IgA or IgM antibody. In some embodiments, IgG comprises IgG1, IgG2, IgG3, IgG4, IgGA1 or IgGA2. In some embodiments, the antibody comprises a chimeric antibody, a humanized antibody, a human antibody, a monoclonal antibody, a deimmunized antibody, a bispecific antibody, a multispecific antibody, a multivalent antibody or a combination thereof. In some embodiments, the antigen binding fragment comprises Fab, Fab', Fab'-SH, Fv, scFv, F(ab')2, a double antibody (diabody), a linear antibody, a single domain antibody (sdAb), a camel VHH domain or a multispecific antibody formed by an antibody fragment. In some embodiments, the antibody or its antigen binding fragment is recombinant or synthetic. In some embodiments, the antibody or its antigen binding fragment also comprises an enzyme, a substrate, a cofactor, a fluorescent marker, a chemiluminescent marker, a peptide tag, a magnetic particle, a drug, a toxin or a combination thereof. In some embodiments, the antibody or its antigen binding fragment has cytolytic properties to tumor cells or cancer cells. In some embodiments, the antibody or its antigen binding fragment inhibits tumor growth or cancer cell growth.

[0010] In some embodiments, the antibody or its antigen-binding fragment can be used to treat cancer. In some embodiments, the antibody or its antigen-binding fragment of the above aspects can be used to treat bladder cancer (e.g., bladder urothelial carcinoma, bladder squamous cell carcinoma, bladder adenocarcinoma or bladder small cell carcinoma), brain cancer (e.g., glioma, meningioma, pituitary adenoma, vestibular schwannoma, schwannoma, primitive neuroectodermal tumor (medulloblastoma), ependymoma, astrocytoma, oligodendroglioma, brain stem glioma, optic nerve glioma, mixed glioma (e.g., oligoastrocytoma), high-grade glioma or low-grade glioma), breast cancer or breast cancer tumor (e.g., invasive ductal carcinoma, ductal carcinoma in situ, invasive lobular carcinoma, lobular carcinoma in situ, inflammatory breast cancer, male breast cancer, phyllodes tumor of the breast, Paget's disease of the nipple (Paget'sdisease of the nipple, angiosarcoma, or metastatic breast cancer), cervical cancer (squamous cell carcinoma of the cervix, adenocarcinoma, adenosquamous carcinoma, small cell carcinoma, neuroendocrine tumor, glassy cell carcinoma, villous tubulocarcinoma, endocervical (NOS) type adenocarcinoma, mucinous adenocarcinoma, minimal deviation adenocarcinoma (mucinous and endometrioid), intestinal / GI type adenocarcinoma, endometrioid type adenocarcinoma, clear cell adenocarcinoma, serous adenocarcinoma, mesonephric duct adenocarcinoma, adenoid basal cell carcinoma, or adenoid cystic carcinoma), bile duct cancer (e.g., intrahepatic bile duct carcinoma, hilar bile duct carcinoma, or distal bile duct carcinoma), colon or rectal cancer (e.g., colon adenocarcinoma, rectal adenocarcinoma, gastrointestinal carcinoid tumor, primary colorectal lymphoma, gastrointestinal stromal tumor, leiomyosarcoma, melanoma, sarcoma, Turcot syndrome (Turcot syndrome), Peutz-Jeghers syndrome, familial colorectal cancer or juvenile polyposis coli), esophageal cancer (e.g.Esophageal cancer is squamous cell carcinoma, adenocarcinoma, choriocarcinoma, lymphoma, melanoma or sarcoma), head and neck squamous cell carcinoma (e.g., conventional squamous cell carcinoma, verrucous carcinoma, basaloid squamous cell carcinoma, papillary squamous cell carcinoma, spindle cell carcinoma, acantholytic squamous cell carcinoma, adenosquamous carcinoma, carcinoma cuniculatum, nasopharyngeal carcinoma, lymphoepithelial carcinoma, laryngeal or hypopharyngeal cancer, nasal cavity cancer or paranasal sinus cancer, nasopharyngeal cancer, oral cavity and oropharyngeal cancer, salivary gland cancer, HPV-negative squamous cell carcinoma or HPV-induced squamous cell carcinoma), kidney cancer (e.g., renal cell carcinoma, renal pelvis cancer, transitional cell carcinoma, squamous cell carcinoma, juxtaglomerular cell tumor (renninoma), angiomyolipoma, Bellini duct cancer renal carcinoma), clear cell sarcoma of the kidney, mesoblastic nephroma, Wilms' tumor, mixed epithelial-stromal tumor, clear cell adenocarcinoma, inverted papilloma, renal lymphoma, teratoma, carcinosarcoma, renal pelvic carcinoid tumor, clear cell renal carcinoma, renal papillary cell carcinoma, sarcomatoid renal cell carcinoma, chromophobe renal cell carcinoma, renal medullary carcinoma, collecting duct renal cell carcinoma, unclassified renal cell carcinoma, renal oncocytoma, angiomyolipoma, or clear cell papillary carcinoma), liver cancer (e.g., hepatocellular carcinoma, fibrolamellar hepatocellular carcinoma, cholangiocarcinoma, mucinous cystic neoplasm, intraductal papillary biliary , hepatoblastoma, bile duct cystadenocarcinoma, angiosarcoma, hemangioendothelioma, embryonal sarcoma, fibrosarcoma, leiomyosarcoma, rhabdomyosarcoma, carcinosarcoma, teratoma, yolk sac tumor, carcinoid tumor, lymphoma or liver metastasis), lung cancer (e.g., non-small cell lung cancer, small cell lung cancer, lung adenocarcinoma, lung squamous cell carcinoma, large cell carcinoma, carcinoid tumor, bronchial adenocarcinoma, carcinosarcoma, pneumoblastoma, giant cell or spindle cell carcinoma or sarcomatoid carcinoma), mesothelioma (e.g., malignant mesothelioma or malignant pleural mesothelioma), cystadenocarcinoma (e.g., ovarian serous cystadenocarcinoma), adenocarcinoma (e.g., pancreatic cancer), pheochromocytoma or paraganglioma, prostate cancer, cutaneous melanoma, gastric adenocarcinoma, testicular germ cell carcinoma, thyroid cancer, uterine cancer (e.g., uterine carcinosarcoma or uterine corpusendometrial carcinoma), uveal melanoma.

[0011] In one aspect, the present invention provides an antibody or an antigen-binding fragment thereof comprising: a variable heavy chain, wherein the variable heavy chain comprises a remodeled polypeptide consensus sequence having at least 95% sequence identity with an amino acid sequence selected from any one of SEQ ID NOs: 1-271; and / or a variable light chain, wherein the variable light chain comprises a remodeled polypeptide consensus sequence having at least 95% sequence identity with an amino acid sequence selected from any one of SEQ ID NOs: 272-542.

[0012] In one aspect, provided herein is a hybridoma that produces the antibody or antigen-binding fragment thereof according to any one of the above aspects.

[0013] Provided herein is a fusion protein comprising the antibody or antigen-binding fragment thereof according to any one of the above aspects.

[0014] Provided herein is a chimeric antigen receptor or T cell receptor fusion protein, comprising: an antigen binding fragment of any one of the above aspects; a transmembrane domain; and an intracellular signaling domain.

[0015] Provided herein is a T cell receptor fusion protein comprising: an antibody or antigen binding fragment thereof of any of the above aspects; and a T cell receptor (TCR) subunit. In some embodiments, the antibody or its antigen binding fragment comprises a human or humanized anti-cancer antigen binding domain. In some embodiments, the TCR subunit comprises: at least a portion of the TCR extracellular domain; a transmembrane domain; and a TCR intracellular domain comprising a stimulatory domain from an intracellular signaling domain. In some embodiments, the extracellular, transmembrane, and intracellular signaling domains of the TCR subunit are derived only from CD3ε or only from CD3γ. In some embodiments, the antibody or its antigen binding fragment and the TCR extracellular domain are connected by a connecting sequence. In some embodiments, the connecting sequence comprises a (G4S)n sequence, wherein G is glycine, S is serine, and n=1 to 4.

[0016] Provided herein is an isolated recombinant nucleic acid molecule encoding the T cell receptor fusion protein of any one of the above aspects.

[0017] Provided herein is a vector comprising the isolated recombinant nucleic acid molecule described above.

[0018] Provided herein is a host cell comprising the isolated recombinant nucleic acid described above or the vector described above. In some embodiments, the host cell is a T cell.

[0019] Provided herein is a T cell expressing a T cell receptor fusion protein of any of the above aspects. In some embodiments, the T cell receptor fusion protein is functionally integrated with an endogenous T cell receptor. In some embodiments, the T cell is a CD8+ or CD4+ T cell.

[0020] Provided herein is an immunoconjugate comprising the antibody or antigen-binding fragment thereof according to any one of the above aspects, and a therapeutic agent.

[0021] Provided herein is a pharmaceutical composition or medicine comprising an antibody or antigen-binding fragment thereof of any of the above aspects, and a pharmaceutically acceptable carrier, excipient or diluent. In some embodiments, the pharmaceutical composition described above further comprises a second therapeutic agent. In some embodiments, the second therapeutic agent comprises a cancer chemotherapeutic agent, radiotherapy, a cytotoxic agent, another antibody, an NSAID, a corticosteroid, a dietary supplement such as an antioxidant, or a combination thereof. In some embodiments, the second therapeutic agent comprises a cancer chemotherapeutic agent. In some embodiments, the pharmaceutical composition of any of the above aspects is formulated for administration via a subcutaneous, intravenous, intradermal, intraperitoneal, intramuscular, intraventricular, intracranial, intracavitary or intracerebellar route of administration. In some embodiments, the pharmaceutical composition of any of the above aspects is in aqueous or lyophilized form. In some embodiments, the pharmaceutical composition of any of the above aspects is contained in a delivery device selected from a group consisting of a syringe, a blunt syringe, a catheter and an implantable pump.

[0022] Provided herein is a use of the antibody or antigen-binding fragment of any one of the above aspects for treating cancer.

[0023] Provided herein is a use of the antibody or antigen-binding fragment of any one of the above aspects or the immunoconjugate described above for the manufacture of a medicament. In some embodiments, the medicament is used to treat cancer.

[0024] Provided herein is a method for treating a subject with cancer, the method comprising administering to the subject a therapeutically effective amount of an antibody or antigen-binding fragment thereof of any of the above aspects. In some embodiments, the antibody or antigen-binding fragment thereof has cytolytic activity against tumor cells. In some embodiments, the antibody or antigen-binding fragment thereof inhibits tumor growth.

[0025] In some embodiments, the cancer is bladder cancer (e.g., urothelial carcinoma of the bladder, squamous cell carcinoma of the bladder, adenocarcinoma of the bladder, or small cell carcinoma of the bladder), brain cancer (e.g., glioma, meningioma, pituitary adenoma, vestibular schwannoma, schwannoma, primitive neuroectodermal tumor (medulloblastoma), ependymoma, astrocytoma, oligodendroglioma, brain stem glioma, optic nerve glioma, mixed glioma (e.g., oligoastrocytoma), high-grade glioma, or low-grade glioma), breast cancer or breast cancer tumor (e.g., invasive ductal carcinoma, ductal carcinoma in situ, invasive lobular carcinoma, lobular carcinoma in situ, inflammatory breast cancer, male breast cancer, phyllodes tumor of the breast, Paget's papillary disease, angiosarcoma, or metastatic breast cancer), cervical cancer (squamous cell carcinoma of the cervix), or cervical cancer. duct carcinoma (e.g., intrahepatic, hilar, or distal bile duct carcinoma), colon or rectal cancer (e.g., colon adenocarcinoma, rectal adenocarcinoma, gastrointestinal carcinoid tumor, primary colorectal lymphoma, gastrointestinal stromal tumor, leiomyosarcoma, melanoma, sarcoma, Turcot syndrome, Peutz-Jeghers syndrome, familial colorectal cancer, or juvenile polyposis coli), esophageal cancer (e.g.,Esophageal cancer is squamous cell carcinoma, adenocarcinoma, choriocarcinoma, lymphoma, melanoma or sarcoma), head and neck squamous cell carcinoma (e.g., conventional squamous cell carcinoma, verrucous carcinoma, basaloid squamous cell carcinoma, papillary squamous cell carcinoma, spindle cell carcinoma, acantholytic squamous cell carcinoma, adenosquamous carcinoma, perforating carcinoma, nasopharyngeal carcinoma, lymphoepithelial carcinoma, laryngeal or hypopharyngeal cancer, nasal cavity cancer or paranasal sinus cancer, nasopharyngeal carcinoma, oral cavity and oropharyngeal cancer, salivary gland cancer, HPV-negative squamous cell carcinoma or HPV-induced squamous cell carcinoma), Renal cancer (e.g., renal cell carcinoma, renal pelvic carcinoma, transitional cell carcinoma, squamous cell carcinoma, juxtaglomerular cell tumor (renninoma), angiomyolipoma, Bellini duct carcinoma, renal clear cell sarcoma, mesoblastic nephroma, Wilms tumor, mixed epithelial-stromal tumor, clear cell adenocarcinoma, inverted papilloma, renal lymphoma, teratoma, carcinosarcoma, renal pelvic carcinoid tumor, renal clear cell carcinoma, renal papillary cell carcinoma, sarcomatoid renal cell carcinoma, chromophobe renal cell carcinoma, renal medullary carcinoma, collecting duct renal cell carcinoma) , unclassified renal cell carcinoma, renal oncocytoma, angiomyolipoma, or clear cell papillary carcinoma), liver cancer (e.g., hepatocellular carcinoma, fibrolamellar hepatocellular carcinoma, cholangiocarcinoma, myxocystic neoplasm, intraductal papilloma of the bile duct, hepatoblastoma, biliary cystadenocarcinoma, angiosarcoma, hemangioendothelioma, embryonal sarcoma, fibrosarcoma, leiomyosarcoma, rhabdomyosarcoma, carcinosarcoma, teratoma, yolk sac tumor, carcinoid tumor, lymphoma, or liver metastasis), lung cancer (e.g., non-small cell lung cancer, small cell lung cancer carcinoma, lung adenocarcinoma, lung squamous cell carcinoma, large cell carcinoma, carcinoid tumor, bronchial adenocarcinoma, carcinosarcoma, pulmonary blastoma, giant cell or spindle cell carcinoma or sarcomatoid carcinoma), mesothelioma (e.g., malignant mesothelioma or malignant pleural mesothelioma), cystadenocarcinoma (e.g., ovarian serous cystadenocarcinoma), adenocarcinoma (e.g., pancreatic cancer), pheochromocytoma or paraganglioma, prostate cancer, skin melanoma, gastric adenocarcinoma, testicular germ cell cancer, thyroid cancer, uterine cancer (e.g., uterine carcinosarcoma or uterine body cancer), uveal melanoma.

[0026] In some embodiments, the antibody or its antigen-binding fragment is administered subcutaneously, intravenously, intradermally, intraperitoneally, orally, intramuscularly or intracranially. In some embodiments, the antibody or its antigen-binding fragment is administered to the subject in combination with a second therapeutic agent. In some embodiments, the second therapeutic agent comprises a cancer chemotherapeutic agent, radiotherapy, a cytotoxic agent, another antibody, an NSAID, a corticosteroid, a dietary supplement such as an antioxidant, or a combination thereof. In some embodiments, the anticancer agent is an anticancer antibody or a chemotherapeutic agent. In some embodiments, the second therapeutic agent is administered before, simultaneously with, or after the administration of the antibody or antigen-binding fragment.

[0027] Provided herein is an isolated nucleic acid molecule comprising at least one of the following: a nucleic acid sequence encoding CDR-H1, wherein the nucleic acid sequence is selected from SEQ ID NOs: 2711-2981; a nucleic acid sequence encoding CDR-H2, wherein the nucleic acid sequence is selected from SEQ ID NOs: 3253-3523; a nucleic acid sequence encoding CDR-H3, wherein the nucleic acid sequence is selected from SEQ ID NOs: 3795-4065; a nucleic acid sequence encoding CDR-L1, wherein the nucleic acid sequence is selected from SEQ ID NOs: 2982-3252; a nucleic acid sequence encoding CDR-L2, wherein the nucleic acid sequence is selected from SEQ ID NOs: 3524-3794; or a nucleic acid sequence encoding CDR-L3, wherein the nucleic acid sequence is selected from SEQ ID NOs: 4066-4336.

[0028] In some embodiments, the nucleic acid sequence is selected from any one of SEQ ID NOs: 2169-2439.

[0029] Provided herein is an isolated nucleic acid molecule comprising a nucleic acid sequence encoding a light chain polypeptide of an antibody, wherein the nucleic acid sequence is selected from any one of SEQ ID NOs: 2440-2710.

[0030] Provided herein is a vector comprising the isolated nucleic acid molecule of any aspect described above.

[0031] The vector of claim 97, wherein the isolated nucleic acid is operably linked to a regulatory sequence.

[0032] Provided herein is a host cell comprising the vector described above or the isolated nucleic acid molecule of any aspect above.

[0033] Provided herein is a method for producing an antibody or an antigen-binding fragment thereof, the method comprising: culturing the host cell described above in a culture medium under conditions that allow expression of the polypeptide encoded by the isolated nucleic acid molecule and assembly of the antibody or the antigen-binding fragment thereof; and purifying the antibody or the antigen-binding fragment thereof from the cultured cells or the cell culture medium.

[0034] Provided herein is a kit comprising a therapeutically effective amount of at least one antibody or antigen-binding fragment thereof of any of the above aspects. In some embodiments, the kit further comprises a therapeutically effective amount of a second therapeutic agent. In some embodiments, the second therapeutic agent is an anticancer agent, radiotherapy, a cytotoxic agent, an NSAID, a corticosteroid, a dietary supplement such as an antioxidant, or a combination thereof. In some embodiments, the anticancer agent is an anticancer antibody or a chemotherapeutic agent. In some embodiments, the antibody or antigen-binding fragment thereof is in a lyophilized or aqueous form. In some embodiments, the kit further comprises a reconstitution solution or a diluent.

[0035] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to R-spondin 1 transcript variant 2 (RSPO1) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 543, a CDR-H2 of SEQ ID NO: 1085, and a CDR-H3 of SEQ ID NO: 1627; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 814, a CDR-L2 of SEQ ID NO: 1356, and a CDR-L3 of SEQ ID NO: 1898. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 272. In some embodiments, the antibody or antigen-binding fragment thereof binds human RSPO1, mouse RSPO1, rat RSPO1, bovine RSPO1, or cynomolgus monkey RSPO1. In some embodiments, human RSPO1 comprises the sequence of SEQ ID NO:4337.

[0036] Provided herein is an antibody that competes for binding to RSPO1 with the antibody or antigen-binding fragment of any one of claims 107 to 110, wherein the antibody binds to human RSPO1 or mouse RSPO1.

[0037] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to zinc finger DHHC-type containing 1 transcript variant 1 (zinc finger DHHC-type containing 1; ZDHHC1) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 545, a CDR-H2 of SEQ ID NO: 1087, and a CDR-H3 of SEQ ID NO: 1629; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 816, a CDR-L2 of SEQ ID NO: 1358, and a CDR-L3 of SEQ ID NO: 1900. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 3, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 274. In some embodiments, the antibody or antigen-binding fragment thereof binds human ZDHHC1, mouse ZDHHC1, rat ZDHHC1, bovine ZDHHC1, or cynomolgus monkey ZDHHC1. In some embodiments, human ZDHHC1 comprises the sequence of SEQ ID NO:4338.

[0038] Provided herein is an antibody that competes for binding to ZDHHC1 with the antibody or antigen-binding fragment of any one of claims 112 to 115, wherein the antibody binds to human ZDHHC1 or mouse ZDHHC1.

[0039] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to retinoid X receptor alpha transcript variant 1 (RXRA) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 546, a CDR-H2 of SEQ ID NO: 1088, and a CDR-H3 of SEQ ID NO: 1630; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 817, a CDR-L2 of SEQ ID NO: 1359, and a CDR-L3 of SEQ ID NO: 1901. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 4, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 275. In some embodiments, the antibody or antigen-binding fragment thereof binds to human RXRA, mouse RXRA, rat RXRA, bovine RXRA, or cynomolgus monkey RXRA. In some embodiments, human RXRA comprises the sequence of SEQ ID NO:4339.

[0040] Provided herein is an antibody that competes for binding to RXRA with the antibody or antigen-binding fragment of any one of claims 117 to 120, wherein the antibody binds to human RXRA or mouse RXRA.

[0041] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to retinoid X receptor gamma transcript variant 1 (RXRG) or a variant thereof, comprising at least one of: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 546, a CDR-H2 of SEQ ID NO: 1088, and a CDR-H3 of SEQ ID NO: 1630; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 817, a CDR-L2 of SEQ ID NO: 1359, and a CDR-L3 of SEQ ID NO: 1901. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 4, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 275. In some embodiments, the antibody or antigen-binding fragment thereof binds human RXRG, mouse RXRG, rat RXRG, bovine RXRG, or cynomolgus monkey RXRG. In some embodiments, human RXRG comprises the sequence of SEQ ID NO:4340.

[0042] Provided herein is an antibody that competes for binding to RXRG with the antibody or antigen-binding fragment of any one of claims 122 to 125, wherein the antibody binds to human RXRG or mouse RXRG.

[0043] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to transmembrane protein 154 (TMEM154) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 547, a CDR-H2 of SEQ ID NO: 1089, and a CDR-H3 of SEQ ID NO: 1631; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 818, a CDR-L2 of SEQ ID NO: 1360, and a CDR-L3 of SEQ ID NO: 1902. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 5, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 276. In some embodiments, the antibody or antigen-binding fragment thereof binds to human TMEM154, mouse TMEM154, rat TMEM154, bovine TMEM154, or cynomolgus monkey TMEM154. In some embodiments, human TMEM154 comprises the sequence of SEQ ID NO: 4341.

[0044] Provided herein is an antibody that competes for binding to TMEM154 with the antibody or antigen-binding fragment of any one of claims 127 to 130, wherein the antibody binds to human TMEM154 or mouse TMEM154.

[0045] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to SNAP associated protein transcript variant 1 (SNAP associated protein; SNAPIN) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 548, a CDR-H2 of SEQ ID NO: 1090, and a CDR-H3 of SEQ ID NO: 1632; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 819, a CDR-L2 of SEQ ID NO: 1361, and a CDR-L3 of SEQ ID NO: 1903. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 6, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 277. In some embodiments, the antibody or antigen-binding fragment thereof binds to human SNAPIN, mouse SNAPIN, rat SNAPIN, bovine SNAPIN or cynomolgus monkey SNAPIN. In some embodiments, the human SNAPIN comprises the sequence of SEQ ID NO:4342.

[0046] Provided herein is an antibody that competes for binding to SNAPIN with the antibody or antigen-binding fragment of any one of claims 132 to 135, wherein the antibody binds to human SNAPIN or mouse SNAPIN.

[0047] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to glycogen phosphorylase L transcript variant 1 (glycogen phosphorylase L; PYGL) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 549, a CDR-H2 of SEQ ID NO: 1091, and a CDR-H3 of SEQ ID NO: 1633; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 820, a CDR-L2 of SEQ ID NO: 1362, and a CDR-L3 of SEQ ID NO: 1904. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 7, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 278. In some embodiments, the antibody or antigen-binding fragment thereof binds human PYGL, mouse PYGL, rat PYGL, bovine PYGL or cynomolgus monkey PYGL. In some embodiments, human PYGL comprises the sequence of SEQ ID NO: 4343.

[0048] Provided herein is an antibody that competes for binding to PYGL with the antibody or antigen-binding fragment of any one of claims 137 to 140, wherein the antibody binds to human PYGL or mouse PYGL.

[0049] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to endoplasmic reticulum calcium binding protein 3 (Reticulocalbin 3; RCN3) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 549, a CDR-H2 of SEQ ID NO: 1091, and a CDR-H3 of SEQ ID NO: 1633; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 820, a CDR-L2 of SEQ ID NO: 1362, and a CDR-L3 of SEQ ID NO: 1904. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 7, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 278. In some embodiments, the antibody or antigen-binding fragment thereof binds human RCN3, mouse RCN3, rat RCN3, bovine RCN3, or cynomolgus monkey RCN3. In some embodiments, human RCN3 comprises the sequence of SEQ ID NO:4344.

[0050] Provided herein is an antibody that competes for binding to RCN3 with the antibody or antigen-binding fragment of any one of claims 142 to 145, wherein the antibody binds to human RCN3 or mouse RCN3.

[0051] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to synaptotagmin 12 transcript variant X4 (synaptotagmin 12; SYT12) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 549, a CDR-H2 of SEQ ID NO: 1091, and a CDR-H3 of SEQ ID NO: 1633; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 820, a CDR-L2 of SEQ ID NO: 1362, and a CDR-L3 of SEQ ID NO: 1904. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 7, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 278. In some embodiments, the antibody or antigen-binding fragment thereof binds human SYT12, mouse SYT12, rat SYT12, bovine SYT12, or cynomolgus monkey SYT12. In some embodiments, human SYT12 comprises the sequence of SEQ ID NO:4345.

[0052] Provided herein is an antibody that competes for binding to SYT12 with the antibody or antigen-binding fragment of any one of claims 147 to 150, wherein the antibody binds to human SYT12 or mouse SYT12.

[0053] Provided herein is an antibody or an antigen-binding fragment thereof, which selectively binds to nuclear receptor subfamily 2 group f member 6 (Nr2f6) or a variant thereof, wherein the antibody or the antigen-binding fragment thereof comprises at least one of the following:

[0054] A variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 550, a CDR-H2 of SEQ ID NO: 1092, and a CDR-H3 of SEQ ID NO: 1634; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 821, a CDR-L2 of SEQ ID NO: 1363, and a CDR-L3 of SEQ ID NO: 1905. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 8, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 279. In some embodiments, the antibody or antigen-binding fragment thereof binds to human Nr2f6, mouse Nr2f6, rat Nr2f6, bovine Nr2f6, or cynomolgus monkey Nr2f6. In some embodiments, human Nr2f6 comprises the sequence of SEQ ID NO:4346.

[0055] Provided herein is an antibody that competes for binding to Nr2f6 with the antibody or antigen-binding fragment of any one of claims 152 to 155, wherein the antibody binds to human Nr2f6 or mouse Nr2f6.

[0056] Provided herein is an antibody or an antigen-binding fragment thereof that selectively binds to protein phosphatase 1 regulatory subunit 13like (PPP1R13L) or a variant thereof, wherein the antibody or antigen-binding fragment thereof comprises at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementary determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 550, a CDR-H2 of SEQ ID NO: 1092, and a CDR-H3 of SEQ ID NO: 1634; and / or a variable light chain region, wherein the variable light chain region comprises a complementary determining region light chain 1 (CDR-L1) of SEQ ID NO: 821, a CDR-L2 of SEQ ID NO: 1363, and a CDR-L3 of SEQ ID NO: 1905. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 8, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 279. In some embodiments, the antibody or antigen-binding fragment thereof binds to human PPP1R13L, mouse PPP1R13L, rat PPP1R13L, bovine PPP1R13L, or cynomolgus monkey PPP1R13L. In some embodiments, human PPP1R13L comprises the sequence of SEQ ID NO: 4347.

[0057] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 157 to 160 for binding to PPP1R13L, wherein the antibody binds to human PPP1R13L or mouse PPP1R13L.

[0058] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to olfactory receptor family 6 subfamily Q member 1 (gene / pseudogene) (olfactory receptor family 6subfamily Q member 1; OR6Q1) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 552, a CDR-H2 of SEQ ID NO: 1094, and a CDR-H3 of SEQ ID NO: 1636; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 823, a CDR-L2 of SEQ ID NO: 1365, and a CDR-L3 of SEQ ID NO: 1907. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 10, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 281. In some embodiments, the antibody or antigen-binding fragment thereof binds human OR6Q1, mouse OR6Q1, rat OR6Q1, bovine OR6Q1, or cynomolgus monkey OR6Q1. In some embodiments, human OR6Q1 comprises the sequence of SEQ ID NO:4348.

[0059] Provided herein is an antibody that competes for binding to OR6Q1 with the antibody or antigen-binding fragment of any one of claims 162 to 165, wherein the antibody binds to human OR6Q1 or mouse OR6Q1.

[0060] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to cancer / testis antigen 1A (CTAG1A) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 553, a CDR-H2 of SEQ ID NO: 1095, and a CDR-H3 of SEQ ID NO: 1637; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 824, a CDR-L2 of SEQ ID NO: 1366, and a CDR-L3 of SEQ ID NO: 1908. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 11, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 282. In some embodiments, the antibody or antigen-binding fragment thereof binds human CTAG1A, mouse CTAG1A, rat CTAG1A, bovine CTAG1A, or cynomolgus monkey CTAG1A. In some embodiments, human CTAG1A comprises the sequence of SEQ ID NO:4349.

[0061] Provided herein is an antibody that competes for binding to CTAG1A with the antibody or antigen-binding fragment of any one of claims 167 to 170, wherein the antibody binds to human CTAG1A or mouse CTAG1A.

[0062] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to cancer / testis antigen 1A (CTAG1A) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 554, a CDR-H2 of SEQ ID NO: 1096, and a CDR-H3 of SEQ ID NO: 1638; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 825, a CDR-L2 of SEQ ID NO: 1367, and a CDR-L3 of SEQ ID NO: 1909. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 12, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 283. In some embodiments, the antibody or antigen-binding fragment thereof binds human CTAG1A, mouse CTAG1A, rat CTAG1A, bovine CTAG1A, or cynomolgus monkey CTAG1A. In some embodiments, human CTAG1A comprises the sequence of SEQ ID NO:4349.

[0063] Provided herein is an antibody that competes for binding to CTAG1A with the antibody or antigen-binding fragment of any one of claims 172 to 175, wherein the antibody binds to human CTAG1A or mouse CTAG1A.

[0064] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to 5-hydroxytryptamine receptor 1E (5-hydroxytryptamine receptor 1E; HTR1E) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 555, a CDR-H2 of SEQ ID NO: 1097, and a CDR-H3 of SEQ ID NO: 1639; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 826, a CDR-L2 of SEQ ID NO: 1368, and a CDR-L3 of SEQ ID NO: 1910. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 13, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 284. In some embodiments, the antibody or antigen-binding fragment thereof binds human HTR1E, mouse HTR1E, rat HTR1E, bovine HTR1E, or cynomolgus monkey HTR1E. In some embodiments, human HTR1E comprises the sequence of SEQ ID NO:4350.

[0065] Provided herein is an antibody that competes for binding to HTR1E with the antibody or antigen-binding fragment of any one of claims 177 to 180, wherein the antibody binds to human HTR1E or mouse HTR1E.

[0066] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to microfibril associated protein 3 transcript variant 3 (MFAP3) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 557, a CDR-H2 of SEQ ID NO: 1099, and a CDR-H3 of SEQ ID NO: 1641; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 828, a CDR-L2 of SEQ ID NO: 1370, and a CDR-L3 of SEQ ID NO: 1912. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 15, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 286. In some embodiments, the antibody or antigen-binding fragment thereof binds human MFAP3, mouse MFAP3, rat MFAP3, bovine MFAP3, or cynomolgus monkey MFAP3. In some embodiments, human MFAP3 comprises the sequence of SEQ ID NO:4351.

[0067] Provided herein is an antibody that competes for binding to MFAP3 with the antibody or antigen-binding fragment of any one of claims 182 to 185, wherein the antibody binds to human MFAP3 or mouse MFAP3.

[0068] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to hyaluronan binding protein 4 (HABP4) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 559, a CDR-H2 of SEQ ID NO: 1101, and a CDR-H3 of SEQ ID NO: 1643; and / or

[0069] A variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 830, a CDR-L2 of SEQ ID NO: 1372, and a CDR-L3 of SEQ ID NO: 1914. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 17, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 288. In some embodiments, the antibody or antigen-binding fragment thereof binds to human HABP4, mouse HABP4, rat HABP4, bovine HABP4, or cynomolgus monkey HABP4. In some embodiments, human HABP4 comprises the sequence of SEQ ID NO: 4352.

[0070] Provided herein is an antibody that competes for binding to HABP4 with the antibody or antigen-binding fragment of any one of claims 187 to 190, wherein the antibody binds to human HABP4 or mouse HABP4.

[0071] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to a glucuronidase beta pseudogene (BC025996.2_frag) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 561, a CDR-H2 of SEQ ID NO: 1103, and a CDR-H3 of SEQ ID NO: 1645; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 832, a CDR-L2 of SEQ ID NO: 1374, and a CDR-L3 of SEQ ID NO: 1916. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 19, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 290. In some embodiments, the antibody or antigen-binding fragment thereof binds human BC025996.2_frag, mouse BC025996.2_frag, rat BC025996.2_frag, bovine BC025996.2_frag or cynomolgus monkey BC025996.2_frag. In some embodiments, human BC025996.2_frag comprises the sequence of SEQ ID NO:4353.

[0072] Provided herein is an antibody that competes for binding to BC025996.2_frag with the antibody or antigen-binding fragment of any one of claims 192 to 195, wherein the antibody binds to human BC025996.2_frag or mouse BC025996.2_frag.

[0073] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to dual-specificity phosphatase 12 (DUSP12) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 562, a CDR-H2 of SEQ ID NO: 1104, and a CDR-H3 of SEQ ID NO: 1646; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 833, a CDR-L2 of SEQ ID NO: 1375, and a CDR-L3 of SEQ ID NO: 1917. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 20, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 291. In some embodiments, the antibody or antigen-binding fragment thereof binds to human DUSP12, mouse DUSP12, rat DUSP12, bovine DUSP12, or cynomolgus monkey DUSP12. In some embodiments, human DUSP12 comprises the sequence of SEQ ID NO:4354.

[0074] Provided herein is an antibody that competes with the antibody or antigen-binding fragment according to any one of claims 197 to 200 for binding to DUSP12, wherein the antibody binds to human DUSP12 or mouse DUSP12.

[0075] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to actinin alpha 1 transcript variant 2 (actinin alpha 1; ACTN1) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 562, a CDR-H2 of SEQ ID NO: 1104, and a CDR-H3 of SEQ ID NO: 1646; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 833, a CDR-L2 of SEQ ID NO: 1375, and a CDR-L3 of SEQ ID NO: 1917. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 20, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 291. In some embodiments, the antibody or antigen-binding fragment thereof binds human ACTN1, mouse ACTN1, rat ACTN1, bovine ACTN1, or cynomolgus monkey ACTN1. In some embodiments, human ACTN1 comprises the sequence of SEQ ID NO:4355.

[0076] Provided herein is an antibody that competes for binding to ACTN1 with the antibody or antigen-binding fragment of any one of claims 202 to 205, wherein the antibody binds to human ACTN1 or mouse ACTN1.

[0077] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to zinc finger transcript variant X1 containing KRAB and SCAN domains 4 (zinc finger with KRAB and SCAN domains 4; ZKSCAN4) or a variant thereof, comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 564, a CDR-H2 of SEQ ID NO: 1106, and a CDR-H3 of SEQ ID NO: 1648; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 835, a CDR-L2 of SEQ ID NO: 1377, and a CDR-L3 of SEQ ID NO: 1919. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 22, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 293. In some embodiments, the antibody or antigen-binding fragment thereof binds human ZKSCAN4, mouse ZKSCAN4, rat ZKSCAN4, bovine ZKSCAN4, or cynomolgus monkey ZKSCAN4. In some embodiments, human ZKSCAN4 comprises the sequence of SEQ ID NO:4356.

[0078] Provided herein is an antibody that competes for binding to ZKSCAN4 with the antibody or antigen-binding fragment of any one of claims 207 to 210, wherein the antibody binds to human ZKSCAN4 or mouse ZKSCAN4.

[0079] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to PNMA family member 5 transcript variant 2 (PNMAfamily member 5; PNMA5) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 566, a CDR-H2 of SEQ ID NO: 1108, and a CDR-H3 of SEQ ID NO: 1650; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 837, a CDR-L2 of SEQ ID NO: 1379, and a CDR-L3 of SEQ ID NO: 1921. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 24, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 295. In some embodiments, the antibody or antigen-binding fragment thereof binds human PNMA5, mouse PNMA5, rat PNMA5, bovine PNMA5, or cynomolgus monkey PNMA5. In some embodiments, human PNMA5 comprises the sequence of SEQ ID NO:4357.

[0080] Provided herein is an antibody that competes for binding to PNMA5 with the antibody or antigen-binding fragment of any one of claims 212 to 215, wherein the antibody binds to human PNMA5 or mouse PNMA5.

[0081] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to kelch like family member 40 (KLHL40) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 567, a CDR-H2 of SEQ ID NO: 1109, and a CDR-H3 of SEQ ID NO: 1651; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 838, a CDR-L2 of SEQ ID NO: 1380, and a CDR-L3 of SEQ ID NO: 1922. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 25, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 296. In some embodiments, the antibody or antigen-binding fragment thereof binds human KLHL40, mouse KLHL40, rat KLHL40, bovine KLHL40, or cynomolgus monkey KLHL40. In some embodiments, human KLHL40 comprises the sequence of SEQ ID NO:4358.

[0082] Provided herein is an antibody that competes for binding to KLHL40 with the antibody or antigen-binding fragment of any one of claims 217 to 220, wherein the antibody binds to human KLHL40 or mouse KLHL40.

[0083] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to membrane palmitoylated protein 2 transcript variant 3 (MPP2) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 567, a CDR-H2 of SEQ ID NO: 1109, and a CDR-H3 of SEQ ID NO: 1651; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 838, a CDR-L2 of SEQ ID NO: 1380, and a CDR-L3 of SEQ ID NO: 1922. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 25, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 296. In some embodiments, the antibody or antigen-binding fragment thereof binds human MPP2, mouse MPP2, rat MPP2, bovine MPP2, or cynomolgus monkey MPP2. In some embodiments, human MPP2 comprises the sequence of SEQ ID NO:4359.

[0084] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 222 to 225 for binding to MPP2, wherein the antibody binds to human MPP2 or mouse MPP2.

[0085] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to butyrophilin subfamily 1 member A1 (BTN1A1) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 568, a CDR-H2 of SEQ ID NO: 1110, and a CDR-H3 of SEQ ID NO: 1652; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 839, a CDR-L2 of SEQ ID NO: 1381, and a CDR-L3 of SEQ ID NO: 1923. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 26, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 297. In some embodiments, the antibody or antigen-binding fragment thereof binds human BTN1A1, mouse BTN1A1, rat BTN1A1, bovine BTN1A1, or cynomolgus monkey BTN1A1. In some embodiments, human BTN1A1 comprises the sequence of SEQ ID NO:4360.

[0086] Provided herein is an antibody that competes for binding to BTN1A1 with the antibody or antigen-binding fragment of any one of claims 227 to 230, wherein the antibody binds to human BTN1A1 or mouse BTN1A1.

[0087] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to peroxisomal biogenesis factor 11gamma (PEX11G) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 569, a CDR-H2 of SEQ ID NO: 1111, and a CDR-H3 of SEQ ID NO: 1653; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 840, a CDR-L2 of SEQ ID NO: 1382, and a CDR-L3 of SEQ ID NO: 1924. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 27, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 298. In some embodiments, the antibody or antigen-binding fragment thereof binds human PEX11G, mouse PEX11G, rat PEX11G, bovine PEX11G, or cynomolgus monkey PEX11G. In some embodiments, human PEX11G comprises the sequence of SEQ ID NO:4361.

[0088] Provided herein is an antibody that competes for binding to PEX11G with the antibody or antigen-binding fragment according to any one of claims 232 to 235, wherein the antibody binds to human PEX11G or mouse PEX11G.

[0089] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to zinc finger protein 8 (ZNF8) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 572, a CDR-H2 of SEQ ID NO: 1114, and a CDR-H3 of SEQ ID NO: 1656; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 843, a CDR-L2 of SEQ ID NO: 1385, and a CDR-L3 of SEQ ID NO: 1927. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 30, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 301. In some embodiments, the antibody or antigen-binding fragment thereof binds human ZNF8, mouse ZNF8, rat ZNF8, bovine ZNF8, or cynomolgus monkey ZNF8. In some embodiments, human ZNF8 comprises the sequence of SEQ ID NO:4362.

[0090] Provided herein is an antibody that competes for binding to ZNF8 with the antibody or antigen-binding fragment of any one of claims 237 to 240, wherein the antibody binds to human ZNF8 or mouse ZNF8.

[0091] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to SATB homeobox 2 transcript variant 2 (SATB homeobox 2; SATB2) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 572, a CDR-H2 of SEQ ID NO: 1114, and a CDR-H3 of SEQ ID NO: 1656; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 843, a CDR-L2 of SEQ ID NO: 1385, and a CDR-L3 of SEQ ID NO: 1927. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 30, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 301. In some embodiments, the antibody or antigen-binding fragment thereof binds to human SATB2, mouse SATB2, rat SATB2, bovine SATB2 or cynomolgus monkey SATB2. In some embodiments, human SATB2 comprises the sequence of SEQ ID NO:4363.

[0092] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 242 to 245 for binding to SATB2, wherein the antibody binds to human SATB2 or mouse SATB2.

[0093] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to ganglioside induced differentiation associated protein 1 transcript variant 2 (ganglioside induced differentiation associated protein 1; GDAP1) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 572, a CDR-H2 of SEQ ID NO: 1114, and a CDR-H3 of SEQ ID NO: 1656; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 843, a CDR-L2 of SEQ ID NO: 1385, and a CDR-L3 of SEQ ID NO: 1927. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 30, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 301. In some embodiments, the antibody or antigen-binding fragment thereof binds human GDAP1, mouse GDAP1, rat GDAP1, bovine GDAP1, or cynomolgus monkey GDAP1. In some embodiments, human GDAP1 comprises the sequence of SEQ ID NO:4364.

[0094] Provided herein is an antibody that competes for binding to GDAP1 with the antibody or antigen-binding fragment of any one of claims 247 to 250, wherein the antibody binds to human GDAP1 or mouse GDAP1.

[0095] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to catenin alpha like 1 transcript variant 1 (CTNNAL1) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 578, a CDR-H2 of SEQ ID NO: 1120, and a CDR-H3 of SEQ ID NO: 1662; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 849, a CDR-L2 of SEQ ID NO: 1391, and a CDR-L3 of SEQ ID NO: 1933. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 36, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 307. In some embodiments, the antibody or antigen-binding fragment thereof binds human CTNNAL1, mouse CTNNAL1, rat CTNNAL1, bovine CTNNAL1, or cynomolgus monkey CTNNAL1. In some embodiments, human CTNNAL1 comprises the sequence of SEQ ID NO:4365.

[0096] Provided herein is an antibody that competes for binding to CTNNAL1 with the antibody or antigen-binding fragment of any one of claims 252 to 255, wherein the antibody binds to human CTNNAL1 or mouse CTNNAL1.

[0097] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to FA complementation group G (FANCG) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 579, a CDR-H2 of SEQ ID NO: 1121, and a CDR-H3 of SEQ ID NO: 1663; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 850, a CDR-L2 of SEQ ID NO: 1392, and a CDR-L3 of SEQ ID NO: 1934. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 37, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 308. In some embodiments, the antibody or antigen-binding fragment thereof binds human FANCG, mouse FANCG, rat FANCG, bovine FANCG or cynomolgus monkey FANCG. In some embodiments, human FANCG comprises the sequence of SEQ ID NO:4366.

[0098] Provided herein is an antibody that competes for binding to FANCG with the antibody or antigen-binding fragment of any one of claims 257 to 260, wherein the antibody binds to human FANCG or mouse FANCG.

[0099] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to DEAD-box helicase 18 (DDX18) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 582, a CDR-H2 of SEQ ID NO: 1124, and a CDR-H3 of SEQ ID NO: 1666; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 853, a CDR-L2 of SEQ ID NO: 1395, and a CDR-L3 of SEQ ID NO: 1937. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 40, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 311. In some embodiments, the antibody or antigen-binding fragment thereof binds human DDX18, mouse DDX18, rat DDX18, bovine DDX18, or cynomolgus monkey DDX18. In some embodiments, human DDX18 comprises the sequence of SEQ ID NO:4367.

[0100] Provided herein is an antibody that competes for binding to DDX18 with the antibody or antigen-binding fragment of any one of claims 262 to 265, wherein the antibody binds to human DDX18 or mouse DDX18.

[0101] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to syntaxin 1A transcript variant 1 (STX1A) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 582, a CDR-H2 of SEQ ID NO: 1124, and a CDR-H3 of SEQ ID NO: 1666; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 853, a CDR-L2 of SEQ ID NO: 1395, and a CDR-L3 of SEQ ID NO: 1937. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 40, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 311. In some embodiments, the antibody or antigen-binding fragment thereof binds human STX1A, mouse STX1A, rat STX1A, bovine STX1A, or cynomolgus monkey STX1A. In some embodiments, human STX1A comprises the sequence of SEQ ID NO:4368.

[0102] Provided herein is an antibody that competes for binding to STX1A with the antibody or antigen-binding fragment of any one of claims 267 to 270, wherein the antibody binds to human STX1A or mouse STX1A.

[0103] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds geminin DNA replication inhibitor transcript variant 1 (GMNN) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 582, a CDR-H2 of SEQ ID NO: 1124, and a CDR-H3 of SEQ ID NO: 1666; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 853, a CDR-L2 of SEQ ID NO: 1395, and a CDR-L3 of SEQ ID NO: 1937. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 40, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 311. In some embodiments, the antibody or antigen-binding fragment thereof binds to human GMNN, mouse GMNN, rat GMNN, bovine GMNN or cynomolgus monkey GMNN. In some embodiments, human GMNN comprises the sequence of SEQ ID NO:4369.

[0104] Provided herein is an antibody that competes for binding to GMNN with the antibody or antigen-binding fragment of any one of claims 272 to 275, wherein the antibody binds to human GMNN or mouse GMNN.

[0105] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to ubiquitin protein 1 transcript variant 2 (ubiquilin1; UBQLN1) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 585, a CDR-H2 of SEQ ID NO: 1127, and a CDR-H3 of SEQ ID NO: 1669; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 856, a CDR-L2 of SEQ ID NO: 1398, and a CDR-L3 of SEQ ID NO: 1940. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 43, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 314. In some embodiments, the antibody or antigen-binding fragment thereof binds human UBQLN1, mouse UBQLN1, rat UBQLN1, bovine UBQLN1, or cynomolgus monkey UBQLN1. In some embodiments, human UBQLN1 comprises the sequence of SEQ ID NO:4370.

[0106] Provided herein is an antibody that competes for binding to UBQLN1 with the antibody or antigen-binding fragment of any one of claims 277 to 280, wherein the antibody binds to human UBQLN1 or mouse UBQLN1.

[0107] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to carnosine dipeptidase 2 transcript variant 1 (CNDP2) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 585, a CDR-H2 of SEQ ID NO: 1127, and a CDR-H3 of SEQ ID NO: 1669; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 856, a CDR-L2 of SEQ ID NO: 1398, and a CDR-L3 of SEQ ID NO: 1940. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 43, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 314. In some embodiments, the antibody or antigen-binding fragment thereof binds to human CNDP2, mouse CNDP2, rat CNDP2, bovine CNDP2 or cynomolgus monkey CNDP2. In some embodiments, human CNDP2 comprises the sequence of SEQ ID NO: 4371.

[0108] Provided herein is an antibody that competes for binding to CNDP2 with the antibody or antigen-binding fragment of any one of claims 282 to 285, wherein the antibody binds to human CNDP2 or mouse CNDP2.

[0109] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to X-linked inhibitor of apoptosis transcript variant 2 (XIAP) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 587, a CDR-H2 of SEQ ID NO: 1129, and a CDR-H3 of SEQ ID NO: 1671; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 858, a CDR-L2 of SEQ ID NO: 1400, and a CDR-L3 of SEQ ID NO: 1942. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 45, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 316. In some embodiments, the antibody or antigen-binding fragment thereof binds human XIAP, mouse XIAP, rat XIAP, bovine XIAP, or cynomolgus monkey XIAP. In some embodiments, human XIAP comprises the sequence of SEQ ID NO: 4372.

[0110] Provided herein is an antibody that competes for binding to XIAP with the antibody or antigen-binding fragment of any one of claims 287 to 290, wherein the antibody binds to human XIAP or mouse XIAP.

[0111] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to hyaluronan binding protein 4 (HABP4) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 587, a CDR-H2 of SEQ ID NO: 1129, and a CDR-H3 of SEQ ID NO: 1671; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 858, a CDR-L2 of SEQ ID NO: 1400, and a CDR-L3 of SEQ ID NO: 1942. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 45, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 316. In some embodiments, the antibody or antigen-binding fragment thereof binds human HABP4, mouse HABP4, rat HABP4, bovine HABP4, or cynomolgus monkey HABP4. In some embodiments, human HABP4 comprises the sequence of SEQ ID NO:4352.

[0112] Provided herein is an antibody that competes for binding to HABP4 with the antibody or antigen-binding fragment of any one of claims 292 to 295, wherein the antibody binds to human HABP4 or mouse HABP4.

[0113] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to endosome associated trafficking regulator 1 transcript variant 2 (SDCCAG3) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 589, a CDR-H2 of SEQ ID NO: 1131, and a CDR-H3 of SEQ ID NO: 1673; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 860, a CDR-L2 of SEQ ID NO: 1402, and a CDR-L3 of SEQ ID NO: 1944. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 47, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 318. In some embodiments, the antibody or antigen-binding fragment thereof binds to human SDCCAG3, mouse SDCCAG3, rat SDCCAG3, bovine SDCCAG3 or cynomolgus monkey SDCCAG3. In some embodiments, human SDCCAG3 comprises the sequence of SEQ ID NO:4373.

[0114] Provided herein is an antibody that competes for binding to SDCCAG3 with the antibody or antigen-binding fragment according to any one of claims 297 to 300, wherein the antibody binds to human SDCCAG3 or mouse SDCCAG3.

[0115] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to charged multivesicular body protein 4B (CHMP4B) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 589, a CDR-H2 of SEQ ID NO: 1131, and a CDR-H3 of SEQ ID NO: 1673; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 860, a CDR-L2 of SEQ ID NO: 1402, and a CDR-L3 of SEQ ID NO: 1944. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 47, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 318. In some embodiments, the antibody or antigen-binding fragment thereof binds human CHMP4B, mouse CHMP4B, rat CHMP4B, bovine CHMP4B, or cynomolgus monkey CHMP4B. In some embodiments, human CHMP4B comprises the sequence of SEQ ID NO:4374.

[0116] Provided herein is an antibody that competes for binding to CHMP4B with the antibody or antigen-binding fragment according to any one of claims 302 to 305, wherein the antibody binds to human CHMP4B or mouse CHMP4B.

[0117] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to glycogenin 2 transcript variant 2 (glycogenin 2; GYG2) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 590, a CDR-H2 of SEQ ID NO: 1132, and a CDR-H3 of SEQ ID NO: 1674; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 861, a CDR-L2 of SEQ ID NO: 1403, and a CDR-L3 of SEQ ID NO: 1945. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 48, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 319. In some embodiments, the antibody or antigen-binding fragment thereof binds to human GYG2, mouse GYG2, rat GYG2, bovine GYG2 or cynomolgus monkey GYG2. In some embodiments, human GYG2 comprises the sequence of SEQ ID NO:4375.

[0118] Provided herein is an antibody that competes for binding to GYG2 with the antibody or antigen-binding fragment of any one of claims 307 to 310, wherein the antibody binds to human GYG2 or mouse GYG2.

[0119] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to an Egf like and emi domain containing 1, pseudogene (EGFEM1P) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 591, a CDR-H2 of SEQ ID NO: 1133, and a CDR-H3 of SEQ ID NO: 1675; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 862, a CDR-L2 of SEQ ID NO: 1404, and a CDR-L3 of SEQ ID NO: 1946. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 49, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 320. In some embodiments, the antibody or antigen-binding fragment thereof binds human EGFEM1P, mouse EGFEM1P, rat EGFEM1P, bovine EGFEM1P, or cynomolgus monkey EGFEM1P. In some embodiments, human EGFEM1P comprises the sequence of SEQ ID NO:4376.

[0120] Provided herein is an antibody that competes for binding to EGFEM1P with the antibody or antigen-binding fragment according to any one of claims 312 to 315, wherein the antibody binds to human EGFEM1P or mouse EGFEM1P.

[0121] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to actinin alpha 4 transcript variant 1 (ACTN4) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 593, a CDR-H2 of SEQ ID NO: 1135, and a CDR-H3 of SEQ ID NO: 1677; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 864, a CDR-L2 of SEQ ID NO: 1406, and a CDR-L3 of SEQ ID NO: 1948. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 51, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 322. In some embodiments, the antibody or antigen-binding fragment thereof binds human ACTN4, mouse ACTN4, rat ACTN4, bovine ACTN4, or cynomolgus monkey ACTN4. In some embodiments, human ACTN4 comprises the sequence of SEQ ID NO:4377.

[0122] Provided herein is an antibody that competes for binding to ACTN4 with the antibody or antigen-binding fragment of any one of claims 317 to 320, wherein the antibody binds to human ACTN4 or mouse ACTN4.

[0123] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to PNMA family member 5 transcript variant 2 (PNMA5) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 594, a CDR-H2 of SEQ ID NO: 1136, and a CDR-H3 of SEQ ID NO: 1678; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 865, a CDR-L2 of SEQ ID NO: 1407, and a CDR-L3 of SEQ ID NO: 1949. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 52, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 323. In some embodiments, the antibody or antigen-binding fragment thereof binds human PNMA5, mouse PNMA5, rat PNMA5, bovine PNMA5, or cynomolgus monkey PNMA5. In some embodiments, human PNMA5 comprises the sequence of SEQ ID NO:4357.

[0124] Provided herein is an antibody that competes for binding to PNMA5 with the antibody or antigen-binding fragment of any one of claims 322 to 325, wherein the antibody binds to human PNMA5 or mouse PNMA5.

[0125] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to phospholipase C delta 1 transcript variant 2 (phospholipase C delta 1; PLCD1) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 594, a CDR-H2 of SEQ ID NO: 1136, and a CDR-H3 of SEQ ID NO: 1678; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 865, a CDR-L2 of SEQ ID NO: 1407, and a CDR-L3 of SEQ ID NO: 1949. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 52; and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 323. In some embodiments, the antibody or antigen-binding fragment thereof binds human PLCD1, mouse PLCD1, rat PLCD1, bovine PLCD1, or cynomolgus monkey PLCD1. In some embodiments, human PLCD1 comprises the sequence of SEQ ID NO:4378.

[0126] Provided herein is an antibody that competes for binding to PLCD1 with the antibody or antigen-binding fragment of any one of claims 327 to 330, wherein the antibody binds to human PLCD1 or mouse PLCD1.

[0127] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to zinc finger protein 326 transcript variant 1 (zinc finger protein 326; ZNF326) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 594, a CDR-H2 of SEQ ID NO: 1136, and a CDR-H3 of SEQ ID NO: 1678; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 865, a CDR-L2 of SEQ ID NO: 1407, and a CDR-L3 of SEQ ID NO: 1949. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 52, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 323. In some embodiments, the antibody or antigen-binding fragment thereof binds human ZNF326, mouse ZNF326, rat ZNF326, bovine ZNF326, or cynomolgus monkey ZNF326. In some embodiments, human ZNF326 comprises the sequence of SEQ ID NO:4379.

[0128] Provided herein is an antibody that competes for binding to ZNF326 with the antibody or antigen-binding fragment of any one of claims 332 to 335, wherein the antibody binds to human ZNF326 or mouse ZNF326.

[0129] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to -(LN608403.1_frag) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 600, a CDR-H2 of SEQ ID NO: 1142, and a CDR-H3 of SEQ ID NO: 1684; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 871, a CDR-L2 of SEQ ID NO: 1413, and a CDR-L3 of SEQ ID NO: 1955. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 58, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 329. In some embodiments, the antibody or antigen-binding fragment thereof binds human LN608403.1_frag, mouse LN608403.1_frag, rat LN608403.1_frag, bovine LN608403.1_frag or cynomolgus monkey LN608403.1_frag. In some embodiments, human LN608403.1_frag comprises the sequence of SEQ ID NO:4380.

[0130] Provided herein is an antibody that competes for binding to LN608403.1_frag with the antibody or antigen-binding fragment of any one of claims 337 to 340, wherein the antibody binds to human LN608403.1_frag or mouse LN608403.1_frag.

[0131] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to JPX transcript XIST activating factor (JPX_frag) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 600, a CDR-H2 of SEQ ID NO: 1142, and a CDR-H3 of SEQ ID NO: 1684; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 871, a CDR-L2 of SEQ ID NO: 1413, and a CDR-L3 of SEQ ID NO: 1955. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 58, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 329. In some embodiments, the antibody or antigen-binding fragment thereof binds to human JPX_frag, mouse JPX_frag, rat JPX_frag, bovine JPX_frag or cynomolgus monkey JPX_frag. In some embodiments, human JPX_frag comprises the sequence of SEQ ID NO: 4381.

[0132] Provided herein is an antibody that competes for binding to JPX_frag with the antibody or antigen-binding fragment according to any one of claims 342 to 345, wherein the antibody binds to human JPX_frag or mouse JPX_frag.

[0133] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to odorant binding protein 2A transcript variant alpha (OBP2A) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 600, a CDR-H2 of SEQ ID NO: 1142, and a CDR-H3 of SEQ ID NO: 1684; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 871, a CDR-L2 of SEQ ID NO: 1413, and a CDR-L3 of SEQ ID NO: 1955. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 58, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 329. In some embodiments, the antibody or antigen-binding fragment thereof binds human OBP2A, mouse OBP2A, rat OBP2A, bovine OBP2A, or cynomolgus monkey OBP2A. In some embodiments, human OBP2A comprises the sequence of SEQ ID NO:4382.

[0134] Provided herein is an antibody that competes for binding to OBP2A with the antibody or antigen-binding fragment of any one of claims 347 to 350, wherein the antibody binds to human OBP2A or mouse OBP2A.

[0135] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to myelin transcription factor 1-like protein transcript variant 2 (MYT1L) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 604, a CDR-H2 of SEQ ID NO: 1146, and a CDR-H3 of SEQ ID NO: 1688; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 875, a CDR-L2 of SEQ ID NO: 1417, and a CDR-L3 of SEQ ID NO: 1959. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 62, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 333. In some embodiments, the antibody or antigen-binding fragment thereof binds human MYT1L, mouse MYT1L, rat MYT1L, bovine MYT1L, or cynomolgus monkey MYT1L. In some embodiments, human MYT1L comprises the sequence of SEQ ID NO:4383.

[0136] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 352 to 355 for binding to MYT1L, wherein the antibody binds to human MYT1L or mouse MYT1L.

[0137] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to heat shock protein family E (Hsp10) member 1 (HSPE1) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 604, a CDR-H2 of SEQ ID NO: 1146, and a CDR-H3 of SEQ ID NO: 1688; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 875, a CDR-L2 of SEQ ID NO: 1417, and a CDR-L3 of SEQ ID NO: 1959. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 62, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 333. In some embodiments, the antibody or antigen-binding fragment thereof binds human HSPE1, mouse HSPE1, rat HSPE1, bovine HSPE1, or cynomolgus monkey HSPE1. In some embodiments, human HSPE1 comprises the sequence of SEQ ID NO:4384.

[0138] Provided herein is an antibody that competes for binding to HSPE1 with the antibody or antigen-binding fragment of any one of claims 357 to 360, wherein the antibody binds to human HSPE1 or mouse HSPE1.

[0139] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to kelch like ECH associated protein 1 transcript variant 1 (KEAP1) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 607, a CDR-H2 of SEQ ID NO: 1149, and a CDR-H3 of SEQ ID NO: 1691; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 878, a CDR-L2 of SEQ ID NO: 1420, and a CDR-L3 of SEQ ID NO: 1962. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 65, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 336. In some embodiments, the antibody or antigen-binding fragment thereof binds human KEAP1, mouse KEAP1, rat KEAP1, bovine KEAP1, or cynomolgus monkey KEAP1. In some embodiments, human KEAP1 comprises the sequence of SEQ ID NO:4385.

[0140] Provided herein is an antibody that competes for binding to KEAP1 with the antibody or antigen-binding fragment of any one of claims 362 to 365, wherein the antibody binds to human KEAP1 or mouse KEAP1.

[0141] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to nucleosome assembly protein 1 like 1 (NAP1L1) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 614, a CDR-H2 of SEQ ID NO: 1156, and a CDR-H3 of SEQ ID NO: 1698; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 885, a CDR-L2 of SEQ ID NO: 1427, and a CDR-L3 of SEQ ID NO: 1969. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 72, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 343. In some embodiments, the antibody or antigen-binding fragment thereof binds human NAP1L1, mouse NAP1L1, rat NAP1L1, bovine NAP1L1, or cynomolgus monkey NAP1L1. In some embodiments, human NAP1L1 comprises the sequence of SEQ ID NO:4386.

[0142] Provided herein is an antibody that competes for binding to NAP1L1 with the antibody or antigen-binding fragment of any one of claims 367 to 370, wherein the antibody binds to human NAP1L1 or mouse NAP1L1.

[0143] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to nudE neurodevelopmental protein 1 transcript variant 1 (nudE neurodevelopmental protein 1; NDE1) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 615, a CDR-H2 of SEQ ID NO: 1157, and a CDR-H3 of SEQ ID NO: 1699; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 886, a CDR-L2 of SEQ ID NO: 1428, and a CDR-L3 of SEQ ID NO: 1970. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 73, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 344. In some embodiments, the antibody or antigen-binding fragment thereof binds human NDE1, mouse NDE1, rat NDE1, bovine NDE1, or cynomolgus monkey NDE1. In some embodiments, human NDE1 comprises the sequence of SEQ ID NO:4387.

[0144] Provided herein is an antibody that competes for binding to NDE1 with the antibody or antigen-binding fragment of any one of claims 372 to 375, wherein the antibody binds to human NDE1 or mouse NDE1.

[0145] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to TruB pseudouridine synthase family member 1 (TRUB1) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 616, a CDR-H2 of SEQ ID NO: 1158, and a CDR-H3 of SEQ ID NO: 1700; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 887, a CDR-L2 of SEQ ID NO: 1429, and a CDR-L3 of SEQ ID NO: 1971. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 74, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 345. In some embodiments, the antibody or antigen-binding fragment thereof binds human TRUB1, mouse TRUB1, rat TRUB1, bovine TRUB1, or cynomolgus monkey TRUB1. In some embodiments, human TRUB1 comprises the sequence of SEQ ID NO:4388.

[0146] Provided herein is an antibody that competes for binding to TRUB1 with the antibody or antigen-binding fragment of any one of claims 377 to 380, wherein the antibody binds to human TRUB1 or mouse TRUB1.

[0147] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to inosine monophosphate dehydrogenase 2 (IMPDH2) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 616, a CDR-H2 of SEQ ID NO: 1158, and a CDR-H3 of SEQ ID NO: 1700; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 887, a CDR-L2 of SEQ ID NO: 1429, and a CDR-L3 of SEQ ID NO: 1971. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 74; and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 345. In some embodiments, the antibody or antigen-binding fragment thereof binds human IMPDH2, mouse IMPDH2, rat IMPDH2, bovine IMPDH2, or cynomolgus monkey IMPDH2. In some embodiments, human IMPDH2 comprises the sequence of SEQ ID NO:4389.

[0148] Provided herein is an antibody that competes for binding to IMPDH2 with the antibody or antigen-binding fragment of any one of claims 382 to 385, wherein the antibody binds to human IMPDH2 or mouse IMPDH2.

[0149] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to phospholipid scramblase 4 transcript variant X4 (phospholipid scramblase 4; PLSCR4) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 616, a CDR-H2 of SEQ ID NO: 1158, and a CDR-H3 of SEQ ID NO: 1700; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 887, a CDR-L2 of SEQ ID NO: 1429, and a CDR-L3 of SEQ ID NO: 1971. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 74, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 345. In some embodiments, the antibody or antigen-binding fragment thereof binds human PLSCR4, mouse PLSCR4, rat PLSCR4, bovine PLSCR4, or cynomolgus monkey PLSCR4. In some embodiments, human PLSCR4 comprises the sequence of SEQ ID NO:4390.

[0150] Provided herein is an antibody that competes for binding to PLSCR4 with the antibody or antigen-binding fragment of any one of claims 387 to 390, wherein the antibody binds to human PLSCR4 or mouse PLSCR4.

[0151] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to influenza virus NS1A binding protein (IVNS1ABP) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises the complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 617, CDR-H2 of SEQ ID NO: 1159, and CDR-H3 of SEQ ID NO: 1701; and / or

[0152] A variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 888, a CDR-L2 of SEQ ID NO: 1430, and a CDR-L3 of SEQ ID NO: 1972. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 75, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 346. In some embodiments, the antibody or antigen-binding fragment thereof binds to human IVNS1 ABP, mouse IVNS1 ABP, rat IVNS1 ABP, bovine IVNS1 ABP, or cynomolgus monkey IVNS1 ABP. In some embodiments, the human IVNS1 ABP comprises the sequence of SEQ ID NO: 4391.

[0153] Provided herein is an antibody that competes for binding to IVNS1 ABP with the antibody or antigen-binding fragment of any one of claims 392 to 395, wherein the antibody binds to human IVNS1 ABP or mouse IVNS1 ABP.

[0154] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to a dishevelled segment polarity protein 3 (DVL3) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 618, a CDR-H2 of SEQ ID NO: 1160, and a CDR-H3 of SEQ ID NO: 1702; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 889, a CDR-L2 of SEQ ID NO: 1431, and a CDR-L3 of SEQ ID NO: 1973. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 76, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 347. In some embodiments, the antibody or antigen-binding fragment thereof binds to human DVL3, mouse DVL3, rat DVL3, bovine DVL3 or cynomolgus monkey DVL3. In some embodiments, human DVL3 comprises the sequence of SEQ ID NO:4392.

[0155] Provided herein is an antibody that competes for binding to DVL3 with the antibody or antigen-binding fragment of any one of claims 397 to 400, wherein the antibody binds to human DVL3 or mouse DVL3.

[0156] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to zinc finger protein 260 (ZNF260) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 618, a CDR-H2 of SEQ ID NO: 1160, and a CDR-H3 of SEQ ID NO: 1702; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 889, a CDR-L2 of SEQ ID NO: 1431, and a CDR-L3 of SEQ ID NO: 1973. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 76, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 347. In some embodiments, the antibody or antigen-binding fragment thereof binds human ZNF260, mouse ZNF260, rat ZNF260, bovine ZNF260, or cynomolgus monkey ZNF260. In some embodiments, human ZNF260 comprises the sequence of SEQ ID NO:4393.

[0157] Provided herein is an antibody that competes for binding to ZNF260 with the antibody or antigen-binding fragment of any one of claims 402 to 405, wherein the antibody binds to human ZNF260 or mouse ZNF260.

[0158] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to sorting nexin 33 transcript variant 1 (sorting nexin 33; SNX33) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 619, a CDR-H2 of SEQ ID NO: 1161, and a CDR-H3 of SEQ ID NO: 1703; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 890, a CDR-L2 of SEQ ID NO: 1432, and a CDR-L3 of SEQ ID NO: 1974. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 77, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 348. In some embodiments, the antibody or antigen-binding fragment thereof binds human SNX33, mouse SNX33, rat SNX33, bovine SNX33, or cynomolgus monkey SNX33. In some embodiments, human SNX33 comprises the sequence of SEQ ID NO:4394.

[0159] Provided herein is an antibody that competes for binding to SNX33 with the antibody or antigen-binding fragment of any one of claims 407 to 410, wherein the antibody binds to human SNX33 or mouse SNX33.

[0160] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to Jupiter microtubule associated homolog 2 (HN1L) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 620, a CDR-H2 of SEQ ID NO: 1162, and a CDR-H3 of SEQ ID NO: 1704; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 891, a CDR-L2 of SEQ ID NO: 1433, and a CDR-L3 of SEQ ID NO: 1975. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 78, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 349. In some embodiments, the antibody or antigen-binding fragment thereof binds human HN1L, mouse HN1L, rat HN1L, bovine HN1L, or cynomolgus monkey HN1L. In some embodiments, human HN1L comprises the sequence of SEQ ID NO:4395.

[0161] Provided herein is an antibody that competes for binding to HN1L with the antibody or antigen-binding fragment of any one of claims 412 to 415, wherein the antibody binds to human HN1L or mouse HN1L.

[0162] Provided herein is an antibody or an antigen-binding fragment thereof that selectively binds to thioesterase superfamily member 6 transcript variant 1 (THEM6) or a variant thereof, wherein the antibody or the antigen-binding fragment thereof comprises at least one of the following:

[0163] A variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 620, a CDR-H2 of SEQ ID NO: 1162, and a CDR-H3 of SEQ ID NO: 1704; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 891, a CDR-L2 of SEQ ID NO: 1433, and a CDR-L3 of SEQ ID NO: 1975. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 78, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 349. In some embodiments, the antibody or antigen-binding fragment thereof binds to human THEM6, mouse THEM6, rat THEM6, bovine THEM6, or cynomolgus monkey THEM6. In some embodiments, human THEM6 comprises the sequence of SEQ ID NO: 4396.

[0164] Provided herein is an antibody that competes for binding to THEM6 with the antibody or antigen-binding fragment of any one of claims 417 to 420, wherein the antibody binds to human THEM6 or mouse THEM6.

[0165] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to a KH RNA binding domain-containing signal transduction-related protein 2 transcript variant 2 (KHDRBS2) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 621, a CDR-H2 of SEQ ID NO: 1163, and a CDR-H3 of SEQ ID NO: 1705; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 892, a CDR-L2 of SEQ ID NO: 1434, and a CDR-L3 of SEQ ID NO: 1976. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 79, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 350. In some embodiments, the antibody or antigen-binding fragment thereof binds human KHDRBS2, mouse KHDRBS2, rat KHDRBS2, bovine KHDRBS2, or cynomolgus monkey KHDRBS2. In some embodiments, human KHDRBS2 comprises the sequence of SEQ ID NO:4397.

[0166] Provided herein is an antibody that competes for binding to KHDRBS2 with the antibody or antigen-binding fragment of any one of claims 422 to 425, wherein the antibody binds to human KHDRBS2 or mouse KHDRBS2.

[0167] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds complement C1q like 3 (C1QL3) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 622, a CDR-H2 of SEQ ID NO: 1164, and a CDR-H3 of SEQ ID NO: 1706; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 893, a CDR-L2 of SEQ ID NO: 1435, and a CDR-L3 of SEQ ID NO: 1977. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 80, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 351. In some embodiments, the antibody or antigen-binding fragment thereof binds human C1QL3, mouse C1QL3, rat C1QL3, bovine C1QL3, or cynomolgus monkey C1QL3. In some embodiments, human C1QL3 comprises the sequence of SEQ ID NO: 4398.

[0168] Provided herein is an antibody that competes for binding to C1QL3 with the antibody or antigen-binding fragment of any one of claims 427 to 430, wherein the antibody binds to human C1QL3 or mouse C1QL3.

[0169] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to protein phosphatase 1 regulatory subunit 27 (PPP1R27) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 623, a CDR-H2 of SEQ ID NO: 1165, and a CDR-H3 of SEQ ID NO: 1707; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 894, a CDR-L2 of SEQ ID NO: 1436, and a CDR-L3 of SEQ ID NO: 1978. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 81, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 352. In some embodiments, the antibody or antigen-binding fragment thereof binds human PPP1R27, mouse PPP1R27, rat PPP1R27, bovine PPP1R27, or cynomolgus monkey PPP1R27. In some embodiments, human PPP1R27 comprises the sequence of SEQ ID NO:4399.

[0170] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 432 to 435 for binding to PPP1R27, wherein the antibody binds to human PPP1R27 or mouse PPP1R27.

[0171] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to deoxyribonuclease 1-like protein 2 transcript variant 1 (deoxyribonuclease 1like 2; DNASE1L2) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 624, a CDR-H2 of SEQ ID NO: 1166, and a CDR-H3 of SEQ ID NO: 1708; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 895, a CDR-L2 of SEQ ID NO: 1437, and a CDR-L3 of SEQ ID NO: 1979. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 82, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 353. In some embodiments, the antibody or antigen-binding fragment thereof binds to human DNASE1L2, mouse DNASE1L2, rat DNASE1L2, bovine DNASE1L2, or cynomolgus monkey DNASE1L2. In some embodiments, human DNASE1L2 comprises the sequence of SEQ ID NO:4400.

[0172] Provided herein is an antibody that competes with the antibody or antigen-binding fragment according to any one of claims 437 to 440 for binding to DNASE1L2, wherein the antibody binds to human DNASE1L2 or mouse DNASE1L2.

[0173] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to extended synaptotagmin 2 (ESYT2_frag) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 625, a CDR-H2 of SEQ ID NO: 1167, and a CDR-H3 of SEQ ID NO: 1709; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 896, a CDR-L2 of SEQ ID NO: 1438, and a CDR-L3 of SEQ ID NO: 1980. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 83, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 354. In some embodiments, the antibody or antigen-binding fragment thereof binds human ESYT2_frag, mouse ESYT2_frag, rat ESYT2_frag, bovine ESYT2_frag or cynomolgus monkey ESYT2_frag. In some embodiments, human ESYT2_frag comprises the sequence of SEQ ID NO:4401.

[0174] Provided herein is an antibody that competes for binding to ESYT2_frag with the antibody or antigen-binding fragment according to any one of claims 442 to 445, wherein the antibody binds to human ESYT2_frag or mouse ESYT2_frag.

[0175] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to C-C motif chemokine ligand 18 (CCL18) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 626, a CDR-H2 of SEQ ID NO: 1168, and a CDR-H3 of SEQ ID NO: 1710; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 897, a CDR-L2 of SEQ ID NO: 1439, and a CDR-L3 of SEQ ID NO: 1981. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 84, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 355. In some embodiments, the antibody or antigen-binding fragment thereof binds human CCL18, mouse CCL18, rat CCL18, bovine CCL18, or cynomolgus monkey CCL18. In some embodiments, human CCL18 comprises the sequence of SEQ ID NO:4402.

[0176] Provided herein is an antibody that competes for binding to CCL18 with the antibody or antigen-binding fragment of any one of claims 447 to 450, wherein the antibody binds to human CCL18 or mouse CCL18.

[0177] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to a homeobox and leucine zipper encoding gene (HOMEZ) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 627, a CDR-H2 of SEQ ID NO: 1169, and a CDR-H3 of SEQ ID NO: 1711; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 898, a CDR-L2 of SEQ ID NO: 1440, and a CDR-L3 of SEQ ID NO: 1982. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 85, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 356. In some embodiments, the antibody or antigen-binding fragment thereof binds human HOMEZ, mouse HOMEZ, rat HOMEZ, bovine HOMEZ or cynomolgus monkey HOMEZ. In some embodiments, human HOMEZ comprises the sequence of SEQ ID NO:4403.

[0178] Provided herein is an antibody that competes for binding to HOMEZ with the antibody or antigen-binding fragment of any one of claims 452 to 455, wherein the antibody binds to human HOMEZ or mouse HOMEZ.

[0179] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to BAR / IMD domain containing adaptor protein 2 transcript variant 3 (BAIAP2) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 627, a CDR-H2 of SEQ ID NO: 1169, and a CDR-H3 of SEQ ID NO: 1711; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 898, a CDR-L2 of SEQ ID NO: 1440, and a CDR-L3 of SEQ ID NO: 1982. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 85, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 356. In some embodiments, the antibody or antigen-binding fragment thereof binds human BAIAP2, mouse BAIAP2, rat BAIAP2, bovine BAIAP2, or cynomolgus monkey BAIAP2. In some embodiments, human BAIAP2 comprises the sequence of SEQ ID NO:4404.

[0180] Provided herein is an antibody that competes for binding to BAIAP2 with the antibody or antigen-binding fragment of any one of claims 457 to 460, wherein the antibody binds to human BAIAP2 or mouse BAIAP2.

[0181] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to kelch-like ECH-associated protein 1 transcript variant 1 (KEAP1) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 628, a CDR-H2 of SEQ ID NO: 1170, and a CDR-H3 of SEQ ID NO: 1712; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 899, a CDR-L2 of SEQ ID NO: 1441, and a CDR-L3 of SEQ ID NO: 1983. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 86, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 357. In some embodiments, the antibody or antigen-binding fragment thereof binds human KEAP1, mouse KEAP1, rat KEAP1, bovine KEAP1, or cynomolgus monkey KEAP1. In some embodiments, human KEAP1 comprises the sequence of SEQ ID NO:4385.

[0182] Provided herein is an antibody that competes for binding to KEAP1 with the antibody or antigen-binding fragment of any one of claims 462 to 465, wherein the antibody binds to human KEAP1 or mouse KEAP1.

[0183] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to RUN and FYVE domain containing protein 3 transcript variant 2 (RUN and FYVE domain containing 3; RUFY3) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 629, a CDR-H2 of SEQ ID NO: 1171, and a CDR-H3 of SEQ ID NO: 1713; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 900, a CDR-L2 of SEQ ID NO: 1442, and a CDR-L3 of SEQ ID NO: 1984. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 87, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 358. In some embodiments, the antibody or antigen-binding fragment thereof binds human RUFY3, mouse RUFY3, rat RUFY3, bovine RUFY3, or cynomolgus monkey RUFY3. In some embodiments, human RUFY3 comprises the sequence of SEQ ID NO:4405.

[0184] Provided herein is an antibody that competes for binding to RUFY3 with the antibody or antigen-binding fragment of any one of claims 467 to 470, wherein the antibody binds to human RUFY3 or mouse RUFY3.

[0185] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to LIM homeobox 5 (LHX5) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 630, a CDR-H2 of SEQ ID NO: 1172, and a CDR-H3 of SEQ ID NO: 1714; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 901, a CDR-L2 of SEQ ID NO: 1443, and a CDR-L3 of SEQ ID NO: 1985. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 88, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 359. In some embodiments, the antibody or antigen-binding fragment thereof binds human LHX5, mouse LHX5, rat LHX5, bovine LHX5, or cynomolgus monkey LHX5. In some embodiments, human LHX5 comprises the sequence of SEQ ID NO: 4406.

[0186] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 472 to 475 for binding to LHX5, wherein the antibody binds to human LHX5 or mouse LHX5.

[0187] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to growth factor receptor bound protein 2 transcript variant 1 (GRB2) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 630, a CDR-H2 of SEQ ID NO: 1172, and a CDR-H3 of SEQ ID NO: 1714; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 901, a CDR-L2 of SEQ ID NO: 1443, and a CDR-L3 of SEQ ID NO: 1985. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 88, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 359. In some embodiments, the antibody or antigen-binding fragment thereof binds human GRB2, mouse GRB2, rat GRB2, bovine GRB2, or cynomolgus monkey GRB2. In some embodiments, human GRB2 comprises the sequence of SEQ ID NO:4407.

[0188] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 477 to 480 for binding to GRB2, wherein the antibody binds to human GRB2 or mouse GRB2.

[0189] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to tyrosine hydroxylase (TH) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 631, a CDR-H2 of SEQ ID NO: 1173, and a CDR-H3 of SEQ ID NO: 1715; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 902, a CDR-L2 of SEQ ID NO: 1444, and a CDR-L3 of SEQ ID NO: 1986. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 89, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 360. In some embodiments, the antibody or antigen-binding fragment thereof binds to human TH, mouse TH, rat TH, bovine TH, or cynomolgus monkey TH. In some embodiments, the human TH comprises the sequence of SEQ ID NO:4408.

[0190] Provided herein is an antibody that competes for binding to TH with the antibody or antigen-binding fragment of any one of claims 482 to 485, wherein the antibody binds to human TH or mouse TH.

[0191] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to leucine rich repeat containing 28 (LRRC28) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 633, a CDR-H2 of SEQ ID NO: 1175, and a CDR-H3 of SEQ ID NO: 1717; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 904, a CDR-L2 of SEQ ID NO: 1446, and a CDR-L3 of SEQ ID NO: 1988. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 91, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 362. In some embodiments, the antibody or antigen-binding fragment thereof binds human LRRC28, mouse LRRC28, rat LRRC28, bovine LRRC28, or cynomolgus monkey LRRC28. In some embodiments, human LRRC28 comprises the sequence of SEQ ID NO:4409.

[0192] Provided herein is an antibody that competes for binding to LRRC28 with the antibody or antigen-binding fragment of any one of claims 487 to 490, wherein the antibody binds to human LRRC28 or mouse LRRC28.

[0193] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to spermatogenesis associated protein 33 transcript variant 2 (spermatogenesis associated 33; SPATA33) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 635, a CDR-H2 of SEQ ID NO: 1177, and a CDR-H3 of SEQ ID NO: 1719; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 906, a CDR-L2 of SEQ ID NO: 1448, and a CDR-L3 of SEQ ID NO: 1990. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 93, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 364. In some embodiments, the antibody or antigen-binding fragment thereof binds to human SPATA33, mouse SPATA33, rat SPATA33, bovine SPATA33, or cynomolgus monkey SPATA33. In some embodiments, human SPATA33 comprises the sequence of SEQ ID NO:4410.

[0194] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 492 to 495 for binding to SPATA33, wherein the antibody binds to human SPATA33 or mouse SPATA33.

[0195] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to ATPase secretory pathway ca2+ transporter 1 (Atpase secretory pathway ca2+ transporting 1; ATP2C1) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 636, a CDR-H2 of SEQ ID NO: 1178, and a CDR-H3 of SEQ ID NO: 1720; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 907, a CDR-L2 of SEQ ID NO: 1449, and a CDR-L3 of SEQ ID NO: 1991. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 94, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 365. In some embodiments, the antibody or antigen-binding fragment thereof binds human ATP2C1, mouse ATP2C1, rat ATP2C1, bovine ATP2C1, or cynomolgus monkey ATP2C1. In some embodiments, human ATP2C1 comprises the sequence of SEQ ID NO:4411.

[0196] Provided herein is an antibody that competes for binding to ATP2C1 with the antibody or antigen-binding fragment of any one of claims 497 to 500, wherein the antibody binds to human ATP2C1 or mouse ATP2C1.

[0197] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to Teashirt zinc finger homeobox 2 transcript variant 1 (TSHZ2) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 636, a CDR-H2 of SEQ ID NO: 1178, and a CDR-H3 of SEQ ID NO: 1720; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 907, a CDR-L2 of SEQ ID NO: 1449, and a CDR-L3 of SEQ ID NO: 1991. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 94, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 365. In some embodiments, the antibody or antigen-binding fragment thereof binds to human TSHZ2, mouse TSHZ2, rat TSHZ2, bovine TSHZ2, or cynomolgus monkey TSHZ2. In some embodiments, human TSHZ2 comprises the sequence of SEQ ID NO:4412.

[0198] Provided herein is an antibody that competes for binding to TSHZ2 with the antibody or antigen-binding fragment of any one of claims 502 to 505, wherein the antibody binds to human TSHZ2 or mouse TSHZ2.

[0199] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to complement component 4 binding protein beta (C4BPB) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 639, a CDR-H2 of SEQ ID NO: 1181, and a CDR-H3 of SEQ ID NO: 1723; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 910, a CDR-L2 of SEQ ID NO: 1452, and a CDR-L3 of SEQ ID NO: 1994. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 97, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 368. In some embodiments, the antibody or antigen-binding fragment thereof binds human C4BPB, mouse C4BPB, rat C4BPB, bovine C4BPB or cynomolgus monkey C4BPB. In some embodiments, human C4BPB comprises the sequence of SEQ ID NO:4413.

[0200] Provided herein is an antibody that competes for binding to C4BPB with the antibody or antigen-binding fragment of any one of claims 507 to 510, wherein the antibody binds to human C4BPB or mouse C4BPB.

[0201] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to NCCRP1-F-box associated domain-containing protein (NCCRP1) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 640, a CDR-H2 of SEQ ID NO: 1182, and a CDR-H3 of SEQ ID NO: 1724; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 911, a CDR-L2 of SEQ ID NO: 1453, and a CDR-L3 of SEQ ID NO: 1995. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 98, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 369. In some embodiments, the antibody or antigen-binding fragment thereof binds human NCCRP1, mouse NCCRP1, rat NCCRP1, bovine NCCRP1, or cynomolgus monkey NCCRP1. In some embodiments, human NCCRP1 comprises the sequence of SEQ ID NO:4414.

[0202] Provided herein is an antibody that competes for binding to NCCRP1 with the antibody or antigen-binding fragment of any one of claims 512 to 515, wherein the antibody binds to human NCCRP1 or mouse NCCRP1.

[0203] Provided herein is an antibody or an antigen-binding fragment thereof that selectively binds to a coiled-coil domain containing protein 102A transcript variant X1 (coiled-coil domain containing 102A; CCDC102A) or a variant thereof, wherein the antibody or antigen-binding fragment thereof comprises at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 640, a CDR-H2 of SEQ ID NO: 1182, and a CDR-H3 of SEQ ID NO: 1724; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 911, a CDR-L2 of SEQ ID NO: 1453, and a CDR-L3 of SEQ ID NO: 1995. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 98, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 369. In some embodiments, the antibody or antigen-binding fragment thereof binds to human CCDC102A, mouse CCDC102A, rat CCDC102A, bovine CCDC102A, or cynomolgus monkey CCDC102A. In some embodiments, human CCDC102A comprises the sequence of SEQ ID NO: 4415.

[0204] Provided herein is an antibody that competes for binding to CCDC102A with the antibody or antigen-binding fragment of any one of claims 517 to 520, wherein the antibody binds to human CCDC102A or mouse CCDC102A.

[0205] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to RNA binding motif protein 47 transcript variant X10 (RNA binding motif protein 47; RBM47) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 641, a CDR-H2 of SEQ ID NO: 1183, and a CDR-H3 of SEQ ID NO: 1725; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 912, a CDR-L2 of SEQ ID NO: 1454, and a CDR-L3 of SEQ ID NO: 1996. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 99, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 370. In some embodiments, the antibody or antigen-binding fragment thereof binds human RBM47, mouse RBM47, rat RBM47, bovine RBM47, or cynomolgus monkey RBM47. In some embodiments, human RBM47 comprises the sequence of SEQ ID NO:4416.

[0206] Provided herein is an antibody that competes for binding to RBM47 with the antibody or antigen-binding fragment of any one of claims 522 to 525, wherein the antibody binds to human RBM47 or mouse RBM47.

[0207] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to RAD1 checkpoint DNA exonuclease transcript variant 1 (RAD1 checkpoint DNA exonuclease; RAD1) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 643, a CDR-H2 of SEQ ID NO: 1185, and a CDR-H3 of SEQ ID NO: 1727; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 914, a CDR-L2 of SEQ ID NO: 1456, and a CDR-L3 of SEQ ID NO: 1998. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 101, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 372. In some embodiments, the antibody or antigen-binding fragment thereof binds human RAD1, mouse RAD1, rat RAD1, bovine RAD1, or cynomolgus monkey RAD1. In some embodiments, human RAD1 comprises the sequence of SEQ ID NO:4417.

[0208] Provided herein is an antibody that competes for binding to RAD1 with the antibody or antigen-binding fragment of any one of claims 527 to 530, wherein the antibody binds to human RAD1 or mouse RAD1.

[0209] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to microtubule associated scaffold protein 1 (MTUS1) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 643, a CDR-H2 of SEQ ID NO: 1185, and a CDR-H3 of SEQ ID NO: 1727; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 914, a CDR-L2 of SEQ ID NO: 1456, and a CDR-L3 of SEQ ID NO: 1998. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 101, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 372. In some embodiments, the antibody or antigen-binding fragment thereof binds human MTUS1, mouse MTUS1, rat MTUS1, bovine MTUS1, or cynomolgus monkey MTUS1. In some embodiments, human MTUS1 comprises the sequence of SEQ ID NO:4418.

[0210] Provided herein is an antibody that competes for binding to MTUS1 with the antibody or antigen-binding fragment of any one of claims 532 to 535, wherein the antibody binds to human MTUS1 or mouse MTUS1.

[0211] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to kelch-like ECH-associated protein 1 transcript variant 1 (KEAP1) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 645, a CDR-H2 of SEQ ID NO: 1187, and a CDR-H3 of SEQ ID NO: 1729; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 916, a CDR-L2 of SEQ ID NO: 1458, and a CDR-L3 of SEQ ID NO: 2000. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 103, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 374. In some embodiments, the antibody or antigen-binding fragment thereof binds human KEAP1, mouse KEAP1, rat KEAP1, bovine KEAP1, or cynomolgus monkey KEAP1. In some embodiments, human KEAP1 comprises the sequence of SEQ ID NO:4385.

[0212] Provided herein is an antibody that competes for binding to KEAP1 with the antibody or antigen-binding fragment of any one of claims 537 to 540, wherein the antibody binds to human KEAP1 or mouse KEAP1.

[0213] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to PNMA family member 5 transcript variant 2 (PNMA5) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 646, a CDR-H2 of SEQ ID NO: 1188, and a CDR-H3 of SEQ ID NO: 1730; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 917, a CDR-L2 of SEQ ID NO: 1459, and a CDR-L3 of SEQ ID NO: 2001. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 104, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 375. In some embodiments, the antibody or antigen-binding fragment thereof binds human PNMA5, mouse PNMA5, rat PNMA5, bovine PNMA5, or cynomolgus monkey PNMA5. In some embodiments, human PNMA5 comprises the sequence of SEQ ID NO:4357.

[0214] Provided herein is an antibody that competes for binding to PNMA5 with the antibody or antigen-binding fragment of any one of claims 542 to 545, wherein the antibody binds to human PNMA5 or mouse PNMA5.

[0215] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to G protein-coupled receptor 83 transcript variant 1 (G protein-coupled receptor 83; GPR83) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 650, a CDR-H2 of SEQ ID NO: 1192, and a CDR-H3 of SEQ ID NO: 1734; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 921, a CDR-L2 of SEQ ID NO: 1463, and a CDR-L3 of SEQ ID NO: 2005. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 108, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 379. In some embodiments, the antibody or antigen-binding fragment thereof binds human GPR83, mouse GPR83, rat GPR83, bovine GPR83, or cynomolgus monkey GPR83. In some embodiments, human GPR83 comprises the sequence of SEQ ID NO:4419.

[0216] Provided herein is an antibody that competes for binding to GPR83 with the antibody or antigen-binding fragment of any one of claims 547 to 550, wherein the antibody binds to human GPR83 or mouse GPR83.

[0217] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to CDP-diacylglycerol synthase 1 (CDS1) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 651, a CDR-H2 of SEQ ID NO: 1193, and a CDR-H3 of SEQ ID NO: 1735; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 922, a CDR-L2 of SEQ ID NO: 1464, and a CDR-L3 of SEQ ID NO: 2006. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 109, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 380. In some embodiments, the antibody or antigen-binding fragment thereof binds human CDS1, mouse CDS1, rat CDS1, bovine CDS1, or cynomolgus monkey CDS1. In some embodiments, human CDS1 comprises the sequence of SEQ ID NO:4420.

[0218] Provided herein is an antibody that competes for binding to CDS1 with the antibody or antigen-binding fragment of any one of claims 552 to 555, wherein the antibody binds to human CDS1 or mouse CDS1.

[0219] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to dynein axonemal assembly factor 3 transcript variant 3 (DNAAF3) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 651, a CDR-H2 of SEQ ID NO: 1193, and a CDR-H3 of SEQ ID NO: 1735; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 922, a CDR-L2 of SEQ ID NO: 1464, and a CDR-L3 of SEQ ID NO: 2006. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 109, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 380. In some embodiments, the antibody or antigen-binding fragment thereof binds human DNAAF3, mouse DNAAF3, rat DNAAF3, bovine DNAAF3, or cynomolgus monkey DNAAF3. In some embodiments, human DNAAF3 comprises the sequence of SEQ ID NO:4421.

[0220] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 557 to 560 for binding to DNAAF3, wherein the antibody binds to human DNAAF3 or mouse DNAAF3.

[0221] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to calcium-dependent membrane-binding protein 1 transcript variant 2 (copine 1; CPNE1) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 652, a CDR-H2 of SEQ ID NO: 1194, and a CDR-H3 of SEQ ID NO: 1736; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 923, a CDR-L2 of SEQ ID NO: 1465, and a CDR-L3 of SEQ ID NO: 2007. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 110, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 381. In some embodiments, the antibody or antigen-binding fragment thereof binds human CPNE1, mouse CPNE1, rat CPNE1, bovine CPNE1, or cynomolgus monkey CPNE1. In some embodiments, human CPNE1 comprises the sequence of SEQ ID NO:4422.

[0222] Provided herein is an antibody that competes for binding to CPNE1 with the antibody or antigen-binding fragment of any one of claims 562 to 565, wherein the antibody binds to human CPNE1 or mouse CPNE1.

[0223] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to aarF domain containing kinase 5 (ADCK5) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 653, a CDR-H2 of SEQ ID NO: 1195, and a CDR-H3 of SEQ ID NO: 1737; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 924, a CDR-L2 of SEQ ID NO: 1466, and a CDR-L3 of SEQ ID NO: 2008. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 111, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 382. In some embodiments, the antibody or antigen-binding fragment thereof binds human ADCK5, mouse ADCK5, rat ADCK5, bovine ADCK5, or cynomolgus monkey ADCK5. In some embodiments, human ADCK5 comprises the sequence of SEQ ID NO:4423.

[0224] Provided herein is an antibody that competes for binding to ADCK5 with the antibody or antigen-binding fragment of any one of claims 567 to 570, wherein the antibody binds to human ADCK5 or mouse ADCK5.

[0225] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to crystallin alpha B transcript variant 2 (crystallin alpha B; CRYAB) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 655, a CDR-H2 of SEQ ID NO: 1197, and a CDR-H3 of SEQ ID NO: 1739; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 926, a CDR-L2 of SEQ ID NO: 1468, and a CDR-L3 of SEQ ID NO: 2010. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 113, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 384. In some embodiments, the antibody or antigen-binding fragment thereof binds human CRYAB, mouse CRYAB, rat CRYAB, bovine CRYAB or cynomolgus monkey CRYAB. In some embodiments, human CRYAB comprises the sequence of SEQ ID NO:4424.

[0226] Provided herein is an antibody that competes for binding to CRYAB with the antibody or antigen-binding fragment of any one of claims 572 to 575, wherein the antibody binds to human CRYAB or mouse CRYAB.

[0227] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to hematopoietic cell-specific Lyn substrate 1 transcript variant 1 (HCLS1) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 656, a CDR-H2 of SEQ ID NO: 1198, and a CDR-H3 of SEQ ID NO: 1740; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 927, a CDR-L2 of SEQ ID NO: 1469, and a CDR-L3 of SEQ ID NO: 2011. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 114, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 385. In some embodiments, the antibody or antigen-binding fragment thereof binds human HCLS1, mouse HCLS1, rat HCLS1, bovine HCLS1, or cynomolgus monkey HCLS1. In some embodiments, human HCLS1 comprises the sequence of SEQ ID NO:4425.

[0228] Provided herein is an antibody that competes for binding to HCLS1 with the antibody or antigen-binding fragment of any one of claims 577 to 580, wherein the antibody binds to human HCLS1 or mouse HCLS1.

[0229] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to aldo-keto reductase family 1 member B transcript variant 1 (AKR1B1) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 657, a CDR-H2 of SEQ ID NO: 1199, and a CDR-H3 of SEQ ID NO: 1741; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 928, a CDR-L2 of SEQ ID NO: 1470, and a CDR-L3 of SEQ ID NO: 2012. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 115, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 386. In some embodiments, the antibody or antigen-binding fragment thereof binds human AKR1B1, mouse AKR1B1, rat AKR1B1, bovine AKR1B1, or cynomolgus monkey AKR1B1. In some embodiments, human AKR1B1 comprises the sequence of SEQ ID NO:4426.

[0230] Provided herein is an antibody that competes for binding to AKR1B1 with the antibody or antigen-binding fragment of any one of claims 582 to 585, wherein the antibody binds to human AKR1B1 or mouse AKR1B1.

[0231] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to surfeit 6 transcript variant 1 (SURF6) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 658, a CDR-H2 of SEQ ID NO: 1200, and a CDR-H3 of SEQ ID NO: 1742; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 929, a CDR-L2 of SEQ ID NO: 1471, and a CDR-L3 of SEQ ID NO: 2013. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 116, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 387. In some embodiments, the antibody or antigen-binding fragment thereof binds human SURF6, mouse SURF6, rat SURF6, bovine SURF6, or cynomolgus monkey SURF6. In some embodiments, human SURF6 comprises the sequence of SEQ ID NO: 4427.

[0232] Provided herein is an antibody that competes for binding to SURF6 with the antibody or antigen-binding fragment of any one of claims 587 to 590, wherein the antibody binds to human SURF6 or mouse SURF6.

[0233] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to proliferating cell nuclear antigen transcript variant 1 (PCNA) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 658, a CDR-H2 of SEQ ID NO: 1200, and a CDR-H3 of SEQ ID NO: 1742; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 929, a CDR-L2 of SEQ ID NO: 1471, and a CDR-L3 of SEQ ID NO: 2013. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 116, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 387. In some embodiments, the antibody or antigen-binding fragment thereof binds to human PCNA, mouse PCNA, rat PCNA, bovine PCNA or cynomolgus PCNA. In some embodiments, human PCNA comprises the sequence of SEQ ID NO:4428.

[0234] Provided herein is an antibody that competes for binding to PCNA with the antibody or antigen-binding fragment of any one of claims 592 to 595, wherein the antibody binds to human PCNA or mouse PCNA.

[0235] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to S100 calcium binding protein B (S100B) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 663, a CDR-H2 of SEQ ID NO: 1205, and a CDR-H3 of SEQ ID NO: 1747; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 934, a CDR-L2 of SEQ ID NO: 1476, and a CDR-L3 of SEQ ID NO: 2018. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 121, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 392. In some embodiments, the antibody or antigen-binding fragment thereof binds human S100B, mouse S100B, rat S100B, bovine S100B, or cynomolgus monkey S100B. In some embodiments, human S100B comprises the sequence of SEQ ID NO:4429.

[0236] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 597 to 600 for binding to S100B, wherein the antibody binds to human S100B or mouse S100B.

[0237] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to check point kinase 2 transcript variant 3 (CHEK2) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 664, a CDR-H2 of SEQ ID NO: 1206, and a CDR-H3 of SEQ ID NO: 1748; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 935, a CDR-L2 of SEQ ID NO: 1477, and a CDR-L3 of SEQ ID NO: 2019. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 122, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 393. In some embodiments, the antibody or antigen-binding fragment thereof binds human CHEK2, mouse CHEK2, rat CHEK2, bovine CHEK2, or cynomolgus monkey CHEK2. In some embodiments, human CHEK2 comprises the sequence of SEQ ID NO:4430.

[0238] Provided herein is an antibody that competes for binding to CHEK2 with the antibody or antigen-binding fragment of any one of claims 602 to 605, wherein the antibody binds to human CHEK2 or mouse CHEK2.

[0239] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to ankyrin repeat domain 53 transcript variant 2 (ANKRD53) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 670, a CDR-H2 of SEQ ID NO: 1212, and a CDR-H3 of SEQ ID NO: 1754; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 941, a CDR-L2 of SEQ ID NO: 1483, and a CDR-L3 of SEQ ID NO: 2025. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 128, and

[0240] The variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 399. In some embodiments, the antibody or antigen-binding fragment thereof binds to human ANKRD53, mouse ANKRD53, rat ANKRD53, bovine ANKRD53, or cynomolgus monkey ANKRD53. In some embodiments, human ANKRD53 comprises the sequence of SEQ ID NO: 4431.

[0241] Provided herein is an antibody that competes for binding to ANKRD53 with the antibody or antigen-binding fragment of any one of claims 607 to 610, wherein the antibody binds to human ANKRD53 or mouse ANKRD53.

[0242] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to killer cell lectin-like receptor g2 (KLRG2) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 683, a CDR-H2 of SEQ ID NO: 1225, and a CDR-H3 of SEQ ID NO: 1767; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 954, a CDR-L2 of SEQ ID NO: 1496, and a CDR-L3 of SEQ ID NO: 2038. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 141, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 412. In some embodiments, the antibody or antigen-binding fragment thereof binds human KLRG2, mouse KLRG2, rat KLRG2, bovine KLRG2, or cynomolgus monkey KLRG2. In some embodiments, human KLRG2 comprises the sequence of SEQ ID NO:4432.

[0243] Provided herein is an antibody that competes for binding to KLRG2 with the antibody or antigen-binding fragment of any one of claims 612 to 615, wherein the antibody binds to human KLRG2 or mouse KLRG2.

[0244] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to a ripartite motif containing 35 (TRIM35) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 683, a CDR-H2 of SEQ ID NO: 1225, and a CDR-H3 of SEQ ID NO: 1767; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 954, a CDR-L2 of SEQ ID NO: 1496, and a CDR-L3 of SEQ ID NO: 2038. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 141, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 412. In some embodiments, the antibody or antigen-binding fragment thereof binds human TRIM35, mouse TRIM35, rat TRIM35, bovine TRIM35, or cynomolgus monkey TRIM35. In some embodiments, human TRIM35 comprises the sequence of SEQ ID NO:4433.

[0245] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 617 to 620 for binding to TRIM35, wherein the antibody binds to human TRIM35 or mouse TRIM35.

[0246] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to FMR1 autosomal homolog 2 (FXR2) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 683, a CDR-H2 of SEQ ID NO: 1225, and a CDR-H3 of SEQ ID NO: 1767; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 954, a CDR-L2 of SEQ ID NO: 1496, and a CDR-L3 of SEQ ID NO: 2038. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 141, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 412. In some embodiments, the antibody or antigen-binding fragment thereof binds human FXR2, mouse FXR2, rat FXR2, bovine FXR2, or cynomolgus monkey FXR2. In some embodiments, human FXR2 comprises the sequence of SEQ ID NO:4434.

[0247] Provided herein is an antibody that competes for binding to FXR2 with the antibody or antigen-binding fragment of any one of claims 622 to 625, wherein the antibody binds to human FXR2 or mouse FXR2.

[0248] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to annexin A1 (ANXA1) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 686, a CDR-H2 of SEQ ID NO: 1228, and a CDR-H3 of SEQ ID NO: 1770; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 957, a CDR-L2 of SEQ ID NO: 1499, and a CDR-L3 of SEQ ID NO: 2041. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 144, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 415. In some embodiments, the antibody or antigen-binding fragment thereof binds human ANXA1, mouse ANXA1, rat ANXA1, bovine ANXA1, or cynomolgus monkey ANXA1. In some embodiments, human ANXA1 comprises the sequence of SEQ ID NO:4435.

[0249] Provided herein is an antibody that competes for binding to ANXA1 with the antibody or antigen-binding fragment of any one of claims 627 to 630, wherein the antibody binds to human ANXA1 or mouse ANXA1.

[0250] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to zinc finger protein 287 transcript variant 2 (ZNF287) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 690, a CDR-H2 of SEQ ID NO: 1232, and a CDR-H3 of SEQ ID NO: 1774; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 961, a CDR-L2 of SEQ ID NO: 1503, and a CDR-L3 of SEQ ID NO: 2045. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 148, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 419. In some embodiments, the antibody or antigen-binding fragment thereof binds human ZNF287, mouse ZNF287, rat ZNF287, bovine ZNF287, or cynomolgus monkey ZNF287. In some embodiments, human ZNF287 comprises the sequence of SEQ ID NO:4436.

[0251] Provided herein is an antibody that competes for binding to ZNF287 with the antibody or antigen-binding fragment of any one of claims 632 to 635, wherein the antibody binds to human ZNF287 or mouse ZNF287.

[0252] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to family with sequence similarity 177 member A1 transcript variant 2 (family with sequence similarity 177 member A1; FAM177A1) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 698, a CDR-H2 of SEQ ID NO: 1240, and a CDR-H3 of SEQ ID NO: 1782; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 969, a CDR-L2 of SEQ ID NO: 1511, and a CDR-L3 of SEQ ID NO: 2053. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 156, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 427. In some embodiments, the antibody or antigen-binding fragment thereof binds human FAM177A1, mouse FAM177A1, rat FAM177A1, bovine FAM177A1, or cynomolgus monkey FAM177A1. In some embodiments, human FAM177A1 comprises the sequence of SEQ ID NO:4437.

[0253] Provided herein is an antibody that competes for binding to FAM177A1 with the antibody or antigen-binding fragment of any one of claims 637 to 640, wherein the antibody binds to human FAM177A1 or mouse FAM177A1.

[0254] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to quinone-type dihydropteridine reductase transcript variant 1 (QDPR) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 701, a CDR-H2 of SEQ ID NO: 1243, and a CDR-H3 of SEQ ID NO: 1785; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 972, a CDR-L2 of SEQ ID NO: 1514, and a CDR-L3 of SEQ ID NO: 2056. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 159, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 430. In some embodiments, the antibody or antigen-binding fragment thereof binds to a human QDPR, a mouse QDPR, a rat QDPR, a bovine QDPR, or a cynomolgus monkey QDPR. In some embodiments, the human QDPR comprises the sequence of SEQ ID NO: 4438.

[0255] Provided herein is an antibody that competes for binding to QDPR with the antibody or antigen-binding fragment of any one of claims 642 to 645, wherein the antibody binds to human QDPR or mouse QDPR.

[0256] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to ETS oncogene family member ELK2 pseudogene 1 (BC031259.1_frag) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 703, a CDR-H2 of SEQ ID NO: 1245, and a CDR-H3 of SEQ ID NO: 1787; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 974, a CDR-L2 of SEQ ID NO: 1516, and a CDR-L3 of SEQ ID NO: 2058. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 161, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 432. In some embodiments, the antibody or antigen-binding fragment thereof binds human BC031259.1_frag, mouse BC031259.1_frag, rat BC031259.1_frag, bovine BC031259.1_frag or cynomolgus monkey BC031259.1_frag. In some embodiments, human BC031259.1_frag comprises the sequence of SEQ ID NO:4439.

[0257] Provided herein is an antibody that competes for binding to BC031259.1_frag with the antibody or antigen-binding fragment of any one of claims 647 to 650, wherein the antibody binds to human BC031259.1_frag or mouse BC031259.1_frag.

[0258] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to methyltransferase-like protein 21C (METTL21C) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 703, a CDR-H2 of SEQ ID NO: 1245, and a CDR-H3 of SEQ ID NO: 1787; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 974, a CDR-L2 of SEQ ID NO: 1516, and a CDR-L3 of SEQ ID NO: 2058. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 161, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 432. In some embodiments, the antibody or antigen-binding fragment thereof binds human METTL21C, mouse METTL21C, rat METTL21C, bovine METTL21C, or cynomolgus monkey METTL21C. In some embodiments, human METTL21C comprises the sequence of SEQ ID NO:4440.

[0259] Provided herein is an antibody that competes for binding to METTL21C with the antibody or antigen-binding fragment of any one of claims 652 to 655, wherein the antibody binds to human METTL21C or mouse METTL21C.

[0260] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to hydroxymethylbilane synthase transcript variant X3 (hydroxymethylbilane synthase; HMBS) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 706, a CDR-H2 of SEQ ID NO: 1248, and a CDR-H3 of SEQ ID NO: 1790; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 977, a CDR-L2 of SEQ ID NO: 1519, and a CDR-L3 of SEQ ID NO: 2061. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 164, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 435. In some embodiments, the antibody or antigen-binding fragment thereof binds to human HMBS, mouse HMBS, rat HMBS, bovine HMBS, or cynomolgus monkey HMBS. In some embodiments, human HMBS comprises the sequence of SEQ ID NO:4441.

[0261] Provided herein is an antibody that competes for binding to HMBS with the antibody or antigen-binding fragment of any one of claims 657 to 660, wherein the antibody binds to human HMBS or mouse HMBS.

[0262] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to hook microtubule tethering protein 2 transcript variant 2 (HOOK2) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 706, a CDR-H2 of SEQ ID NO: 1248, and a CDR-H3 of SEQ ID NO: 1790; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 977, a CDR-L2 of SEQ ID NO: 1519, and a CDR-L3 of SEQ ID NO: 2061. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 164, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 435. In some embodiments, the antibody or antigen-binding fragment thereof binds to human HOOK2, mouse HOOK2, rat HOOK2, bovine HOOK2, or cynomolgus monkey HOOK2. In some embodiments, human HOOK2 comprises the sequence of SEQ ID NO:4442.

[0263] Provided herein is an antibody that competes for binding to HOOK2 with the antibody or antigen-binding fragment of any one of claims 662 to 665, wherein the antibody binds to human HOOK2 or mouse HOOK2.

[0264] Provided herein is an antibody or an antigen-binding fragment thereof that selectively binds to Magel2 (Q6ir13_frag) or a variant thereof, wherein the antibody or the antigen-binding fragment thereof comprises at least one of the following:

[0265] A variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 713, a CDR-H2 of SEQ ID NO: 1255, and a CDR-H3 of SEQ ID NO: 1797; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 984, a CDR-L2 of SEQ ID NO: 1526, and a CDR-L3 of SEQ ID NO: 2068. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 171, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 442. In some embodiments, the antibody or antigen-binding fragment thereof binds human Q6ir13_frag, mouse Q6ir13_frag, rat Q6ir13_frag, bovine Q6ir13_frag or cynomolgus monkey Q6ir13_frag. In some embodiments, human Q6ir13_frag comprises the sequence of SEQ ID NO:4443.

[0266] Provided herein is an antibody that competes for binding to Q6ir13_frag with the antibody or antigen-binding fragment of any one of claims 667 to 670, wherein the antibody binds to human Q6ir13_frag or mouse Q6ir13_frag.

[0267] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to serine and arginine rich splicing factor 3 transcript variant 1 (serine and arginine rich splicing factor 3; SRSF3) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 713, a CDR-H2 of SEQ ID NO: 1255, and a CDR-H3 of SEQ ID NO: 1797; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 984, a CDR-L2 of SEQ ID NO: 1526, and a CDR-L3 of SEQ ID NO: 2068. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 171, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 442. In some embodiments, the antibody or antigen-binding fragment thereof binds human SRSF3, mouse SRSF3, rat SRSF3, bovine SRSF3, or cynomolgus monkey SRSF3. In some embodiments, human SRSF3 comprises the sequence of SEQ ID NO:4444.

[0268] Provided herein is an antibody that competes for binding to SRSF3 with the antibody or antigen-binding fragment of any one of claims 672 to 675, wherein the antibody binds to human SRSF3 or mouse SRSF3.

[0269] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to RAN binding protein 10 transcript variant 1 (RANBP10) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 714, a CDR-H2 of SEQ ID NO: 1256, and a CDR-H3 of SEQ ID NO: 1798; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 985, a CDR-L2 of SEQ ID NO: 1527, and a CDR-L3 of SEQ ID NO: 2069. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 172, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 443. In some embodiments, the antibody or antigen-binding fragment thereof binds human RANBP10, mouse RANBP10, rat RANBP10, bovine RANBP10, or cynomolgus monkey RANBP10. In some embodiments, human RANBP10 comprises the sequence of SEQ ID NO:4445.

[0270] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 677 to 680 for binding to RANBP10, wherein the antibody binds to human RANBP10 or mouse RANBP10.

[0271] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to Wnt family member 9b (WNT9B) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 714, a CDR-H2 of SEQ ID NO: 1256, and a CDR-H3 of SEQ ID NO: 1798; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 985, a CDR-L2 of SEQ ID NO: 1527, and a CDR-L3 of SEQ ID NO: 2069. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 172, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 443. In some embodiments, the antibody or antigen-binding fragment thereof binds human WNT9B, mouse WNT9B, rat WNT9B, bovine WNT9B, or cynomolgus monkey WNT9B. In some embodiments, human WNT9B comprises the sequence of SEQ ID NO:4446.

[0272] Provided herein is an antibody that competes for binding to WNT9B with the antibody or antigen-binding fragment of any one of claims 682 to 685, wherein the antibody binds to human WNT9B or mouse WNT9B.

[0273] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to ubiquitin protein 2 (UBQLN2) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 715, a CDR-H2 of SEQ ID NO: 1257, and a CDR-H3 of SEQ ID NO: 1799; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 986, a CDR-L2 of SEQ ID NO: 1528, and a CDR-L3 of SEQ ID NO: 2070. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 173, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 444. In some embodiments, the antibody or antigen-binding fragment thereof binds human UBQLN2, mouse UBQLN2, rat UBQLN2, bovine UBQLN2, or cynomolgus monkey UBQLN2. In some embodiments, human UBQLN2 comprises the sequence of SEQ ID NO:4447.

[0274] Provided herein is an antibody that competes for binding to UBQLN2 with the antibody or antigen-binding fragment of any one of claims 687 to 690, wherein the antibody binds to human UBQLN2 or mouse UBQLN2.

[0275] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to ubiquitin protein 1 transcript variant 2 (UBQLN1) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 715, a CDR-H2 of SEQ ID NO: 1257, and a CDR-H3 of SEQ ID NO: 1799; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 986, a CDR-L2 of SEQ ID NO: 1528, and a CDR-L3 of SEQ ID NO: 2070. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 173, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 444. In some embodiments, the antibody or antigen-binding fragment thereof binds human UBQLN1, mouse UBQLN1, rat UBQLN1, bovine UBQLN1, or cynomolgus monkey UBQLN1. In some embodiments, human UBQLN1 comprises the sequence of SEQ ID NO:4370.

[0276] Provided herein is an antibody that competes for binding to UBQLN1 with the antibody or antigen-binding fragment of any one of claims 692 to 695, wherein the antibody binds to human UBQLN1 or mouse UBQLN1.

[0277] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to ubiquitin protein 3 (UBQLN3) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 715, a CDR-H2 of SEQ ID NO: 1257, and a CDR-H3 of SEQ ID NO: 1799; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 986, a CDR-L2 of SEQ ID NO: 1528, and a CDR-L3 of SEQ ID NO: 2070. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 173, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 444. In some embodiments, the antibody or antigen-binding fragment thereof binds human UBQLN3, mouse UBQLN3, rat UBQLN3, bovine UBQLN3, or cynomolgus monkey UBQLN3. In some embodiments, human UBQLN3 comprises the sequence of SEQ ID NO:4448.

[0278] Provided herein is an antibody that competes for binding to UBQLN3 with the antibody or antigen-binding fragment of any one of claims 697 to 700, wherein the antibody binds to human UBQLN3 or mouse UBQLN3.

[0279] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to anterior gradient 3, protein disulphide isomerase family member (AGR3) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 717, a CDR-H2 of SEQ ID NO: 1259, and a CDR-H3 of SEQ ID NO: 1801; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 988, a CDR-L2 of SEQ ID NO: 1530, and a CDR-L3 of SEQ ID NO: 2072. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 175, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 446. In some embodiments, the antibody or antigen-binding fragment thereof binds human AGR3, mouse AGR3, rat AGR3, bovine AGR3 or cynomolgus monkey AGR3. In some embodiments, human AGR3 comprises the sequence of SEQ ID NO:4449.

[0280] Provided herein is an antibody that competes for binding to AGR3 with the antibody or antigen-binding fragment of any one of claims 702 to 705, wherein the antibody binds to human AGR3 or mouse AGR3.

[0281] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to serine- and arginine-rich splicing factor 3 transcript variant 1 (SRSF3) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 719, a CDR-H2 of SEQ ID NO: 1261, and a CDR-H3 of SEQ ID NO: 1803; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 990, a CDR-L2 of SEQ ID NO: 1532, and a CDR-L3 of SEQ ID NO: 2074. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 177, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 448. In some embodiments, the antibody or antigen-binding fragment thereof binds human SRSF3, mouse SRSF3, rat SRSF3, bovine SRSF3, or cynomolgus monkey SRSF3. In some embodiments, human SRSF3 comprises the sequence of SEQ ID NO:4444.

[0282] Provided herein is an antibody that competes for binding to SRSF3 with the antibody or antigen-binding fragment of any one of claims 707 to 710, wherein the antibody binds to human SRSF3 or mouse SRSF3.

[0283] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to baculoviral IAP repeat containing 7 (BIRC7) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 720, a CDR-H2 of SEQ ID NO: 1262, and a CDR-H3 of SEQ ID NO: 1804; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 991, a CDR-L2 of SEQ ID NO: 1533, and a CDR-L3 of SEQ ID NO: 2075. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 178, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 449. In some embodiments, the antibody or antigen-binding fragment thereof binds human BIRC7, mouse BIRC7, rat BIRC7, bovine BIRC7, or cynomolgus monkey BIRC7. In some embodiments, human BIRC7 comprises the sequence of SEQ ID NO: 4450.

[0284] Provided herein is an antibody that competes for binding to BIRC7 with the antibody or antigen-binding fragment of any one of claims 712 to 715, wherein the antibody binds to human BIRC7 or mouse BIRC7.

[0285] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to endosome-associated transport regulatory factor 1 transcript variant 2 (SDCCAG3) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 722, a CDR-H2 of SEQ ID NO: 1264, and a CDR-H3 of SEQ ID NO: 1806; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 993, a CDR-L2 of SEQ ID NO: 1535, and a CDR-L3 of SEQ ID NO: 2077. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 180, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 451. In some embodiments, the antibody or antigen-binding fragment thereof binds to human SDCCAG3, mouse SDCCAG3, rat SDCCAG3, bovine SDCCAG3 or cynomolgus monkey SDCCAG3. In some embodiments, human SDCCAG3 comprises the sequence of SEQ ID NO:4373.

[0286] Provided herein is an antibody that competes for binding to SDCCAG3 with the antibody or antigen-binding fragment of any one of claims 717 to 720, wherein the antibody binds to human SDCCAG3 or mouse SDCCAG3.

[0287] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to microtubule-associated scaffolding protein 2 transcript variant 2 (MTUS2) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 724, a CDR-H2 of SEQ ID NO: 1266, and a CDR-H3 of SEQ ID NO: 1808; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 995, a CDR-L2 of SEQ ID NO: 1537, and a CDR-L3 of SEQ ID NO: 2079. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 182, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 453. In some embodiments, the antibody or antigen-binding fragment thereof binds to human MTUS2, mouse MTUS2, rat MTUS2, bovine MTUS2, or cynomolgus monkey MTUS2. In some embodiments, human MTUS2 comprises the sequence of SEQ ID NO: 4451.

[0288] Provided herein is an antibody that competes for binding to MTUS2 with the antibody or antigen-binding fragment of any one of claims 722 to 725, wherein the antibody binds to human MTUS2 or mouse MTUS2.

[0289] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to zinc finger protein 296 (ZNF296) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 725, a CDR-H2 of SEQ ID NO: 1267, and a CDR-H3 of SEQ ID NO: 1809; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 996, a CDR-L2 of SEQ ID NO: 1538, and a CDR-L3 of SEQ ID NO: 2080. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 183, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 454. In some embodiments, the antibody or antigen-binding fragment thereof binds human ZNF296, mouse ZNF296, rat ZNF296, bovine ZNF296, or cynomolgus monkey ZNF296. In some embodiments, human ZNF296 comprises the sequence of SEQ ID NO:4452.

[0290] Provided herein is an antibody that competes for binding to ZNF296 with the antibody or antigen-binding fragment of any one of claims 727 to 730, wherein the antibody binds to human ZNF296 or mouse ZNF296.

[0291] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to phosphodiesterase 5A transcript variant 1 (PDE5A) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 725, a CDR-H2 of SEQ ID NO: 1267, and a CDR-H3 of SEQ ID NO: 1809; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 996, a CDR-L2 of SEQ ID NO: 1538, and a CDR-L3 of SEQ ID NO: 2080. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 183, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 454. In some embodiments, the antibody or antigen-binding fragment thereof binds human PDE5A, mouse PDE5A, rat PDE5A, bovine PDE5A or cynomolgus monkey PDE5A. In some embodiments, human PDE5A comprises the sequence of SEQ ID NO:4453.

[0292] Provided herein is an antibody that competes for binding to PDE5A with the antibody or antigen-binding fragment according to any one of claims 732 to 735, wherein the antibody binds to human PDE5A or mouse PDE5A.

[0293] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to Ep400 pseudogene 1 (EP400NL) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 725, a CDR-H2 of SEQ ID NO: 1267, and a CDR-H3 of SEQ ID NO: 1809; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 996, a CDR-L2 of SEQ ID NO: 1538, and a CDR-L3 of SEQ ID NO: 2080. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 183, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 454. In some embodiments, the antibody or antigen-binding fragment thereof binds human EP400NL, mouse EP400NL, rat EP400NL, bovine EP400NL, or cynomolgus monkey EP400NL. In some embodiments, human EP400NL comprises the sequence of SEQ ID NO:4454.

[0294] Provided herein is an antibody that competes for binding to EP400NL with the antibody or antigen-binding fragment according to any one of claims 737 to 740, wherein the antibody binds to human EP400NL or mouse EP400NL.

[0295] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to Bcl2-like protein 1 (BCL2L1) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 727, a CDR-H2 of SEQ ID NO: 1269, and a CDR-H3 of SEQ ID NO: 1811; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 998, a CDR-L2 of SEQ ID NO: 1540, and a CDR-L3 of SEQ ID NO: 2082. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 185, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 456. In some embodiments, the antibody or antigen-binding fragment thereof binds to human BCL2L1, mouse BCL2L1, rat BCL2L1, bovine BCL2L1, or cynomolgus monkey BCL2L1. In some embodiments, human BCL2L1 comprises the sequence of SEQ ID NO:4455.

[0296] Provided herein is an antibody that competes for binding to BCL2L1 with the antibody or antigen-binding fragment of any one of claims 742 to 745, wherein the antibody binds to human BCL2L1 or mouse BCL2L1.

[0297] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to arginine- and glutamate-rich protein 1 (ARGLU1) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 728, a CDR-H2 of SEQ ID NO: 1270, and a CDR-H3 of SEQ ID NO: 1812; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 999, a CDR-L2 of SEQ ID NO: 1541, and a CDR-L3 of SEQ ID NO: 2083. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 186, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 457. In some embodiments, the antibody or antigen-binding fragment thereof binds human ARGLU1, mouse ARGLU1, rat ARGLU1, bovine ARGLU1, or cynomolgus monkey ARGLU1. In some embodiments, human ARGLU1 comprises the sequence of SEQ ID NO:4456.

[0298] Provided herein is an antibody that competes for binding to ARGLU1 with the antibody or antigen-binding fragment of any one of claims 747 to 750, wherein the antibody binds to human ARGLU1 or mouse ARGLU1.

[0299] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to SAS-6 centriolar assembly protein transcript variant 2 (SASS6) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 728, a CDR-H2 of SEQ ID NO: 1270, and a CDR-H3 of SEQ ID NO: 1812; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 999, a CDR-L2 of SEQ ID NO: 1541, and a CDR-L3 of SEQ ID NO: 2083. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 186, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 457. In some embodiments, the antibody or antigen-binding fragment thereof binds human SASS6, mouse SASS6, rat SASS6, bovine SASS6, or cynomolgus monkey SASS6. In some embodiments, human SASS6 comprises the sequence of SEQ ID NO:4457.

[0300] Provided herein is an antibody that competes for binding to SASS6 with the antibody or antigen-binding fragment of any one of claims 752 to 755, wherein the antibody binds to human SASS6 or mouse SASS6.

[0301] Provided herein is an antibody or an antigen-binding fragment thereof that selectively binds to proteasome 26S subunit, non-ATPase 4 transcript variant 2 (PSMD4) or a variant thereof, wherein the antibody or antigen-binding fragment thereof comprises at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 729, a CDR-H2 of SEQ ID NO: 1271, and a CDR-H3 of SEQ ID NO: 1813; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 1000, a CDR-L2 of SEQ ID NO: 1542, and a CDR-L3 of SEQ ID NO: 2084. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 187, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 458. In some embodiments, the antibody or antigen-binding fragment thereof binds to human PSMD4, mouse PSMD4, rat PSMD4, bovine PSMD4, or cynomolgus monkey PSMD4. In some embodiments, human PSMD4 comprises the sequence of SEQ ID NO: 4458.

[0302] Provided herein is an antibody that competes for binding to PSMD4 with the antibody or antigen-binding fragment of any one of claims 757 to 760, wherein the antibody binds to human PSMD4 or mouse PSMD4.

[0303] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to Src-like linker transcript variant 1 (SLA) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 729, a CDR-H2 of SEQ ID NO: 1271, and a CDR-H3 of SEQ ID NO: 1813; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 1000, a CDR-L2 of SEQ ID NO: 1542, and a CDR-L3 of SEQ ID NO: 2084. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 187, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 458. In some embodiments, the antibody or antigen-binding fragment thereof binds to human SLA, mouse SLA, rat SLA, bovine SLA or cynomolgus monkey SLA. In some embodiments, human SLA comprises the sequence of SEQ ID NO:4459.

[0304] Provided herein is an antibody that competes for binding to SLA with the antibody or antigen-binding fragment of any one of claims 762 to 765, wherein the antibody binds to human SLA or mouse SLA.

[0305] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to nudix hydrolase 21 (NUDT21) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 730, a CDR-H2 of SEQ ID NO: 1272, and a CDR-H3 of SEQ ID NO: 1814; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 1001, a CDR-L2 of SEQ ID NO: 1543, and a CDR-L3 of SEQ ID NO: 2085. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 188, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 459. In some embodiments, the antibody or antigen-binding fragment thereof binds human NUDT21, mouse NUDT21, rat NUDT21, bovine NUDT21, or cynomolgus monkey NUDT21. In some embodiments, human NUDT21 comprises the sequence of SEQ ID NO:4460.

[0306] Provided herein is an antibody that competes for binding to NUDT21 with the antibody or antigen-binding fragment of any one of claims 767 to 770, wherein the antibody binds to human NUDT21 or mouse NUDT21.

[0307] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to zinc finger protein 431 transcript variant 2 (ZNF431) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 730, a CDR-H2 of SEQ ID NO: 1272, and a CDR-H3 of SEQ ID NO: 1814; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 1001, a CDR-L2 of SEQ ID NO: 1543, and a CDR-L3 of SEQ ID NO: 2085. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 188, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 459. In some embodiments, the antibody or antigen-binding fragment thereof binds human ZNF431, mouse ZNF431, rat ZNF431, bovine ZNF431, or cynomolgus monkey ZNF431. In some embodiments, human ZNF431 comprises the sequence of SEQ ID NO:4461.

[0308] Provided herein is an antibody that competes for binding to ZNF431 with the antibody or antigen-binding fragment of any one of claims 772 to 775, wherein the antibody binds to human ZNF431 or mouse ZNF431.

[0309] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to zinc finger protein 699 (ZNF699) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 730, a CDR-H2 of SEQ ID NO: 1272, and a CDR-H3 of SEQ ID NO: 1814; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 1001, a CDR-L2 of SEQ ID NO: 1543, and a CDR-L3 of SEQ ID NO: 2085. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 188, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 459. In some embodiments, the antibody or antigen-binding fragment thereof binds human ZNF699, mouse ZNF699, rat ZNF699, bovine ZNF699, or cynomolgus monkey ZNF699. In some embodiments, human ZNF699 comprises the sequence of SEQ ID NO:4462.

[0310] Provided herein is an antibody that competes for binding to ZNF699 with the antibody or antigen-binding fragment of any one of claims 777 to 780, wherein the antibody binds to human ZNF699 or mouse ZNF699.

[0311] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to quinone-type dihydropteridine reductase transcript variant 1 (QDPR) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 731, a CDR-H2 of SEQ ID NO: 1273, and a CDR-H3 of SEQ ID NO: 1815; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 1002, a CDR-L2 of SEQ ID NO: 1544, and a CDR-L3 of SEQ ID NO: 2086. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 189, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 460. In some embodiments, the antibody or antigen-binding fragment thereof binds to a human QDPR, a mouse QDPR, a rat QDPR, a bovine QDPR, or a cynomolgus monkey QDPR. In some embodiments, the human QDPR comprises the sequence of SEQ ID NO: 4438.

[0312] Provided herein is an antibody that competes for binding to QDPR with the antibody or antigen-binding fragment of any one of claims 782 to 785, wherein the antibody binds to human QDPR or mouse QDPR.

[0313] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to PAGE family member 2 (PAGE2) or a variant thereof, wherein the antibody or antigen-binding fragment thereof comprises at least one of the following:

[0314] A variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 732, a CDR-H2 of SEQ ID NO: 1274, and a CDR-H3 of SEQ ID NO: 1816; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 1003, a CDR-L2 of SEQ ID NO: 1545, and a CDR-L3 of SEQ ID NO: 2087. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 190, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 461. In some embodiments, the antibody or antigen-binding fragment thereof binds to human PAGE2, mouse PAGE2, rat PAGE2, bovine PAGE2, or cynomolgus monkey PAGE2. In some embodiments, human PAGE2 comprises the sequence of SEQ ID NO: 4463.

[0315] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 787 to 790 for binding to PAGE2, wherein the antibody binds to human PAGE2 or mouse PAGE2.

[0316] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to keratin associated protein 12-3 (KRTAP12-3) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 732, a CDR-H2 of SEQ ID NO: 1274, and a CDR-H3 of SEQ ID NO: 1816; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 1003, a CDR-L2 of SEQ ID NO: 1545, and a CDR-L3 of SEQ ID NO: 2087. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 190, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 461. In some embodiments, the antibody or antigen-binding fragment thereof binds human KRTAP12-3, mouse KRTAP12-3, rat KRTAP12-3, bovine KRTAP12-3, or cynomolgus monkey KRTAP12-3. In some embodiments, human KRTAP12-3 comprises the sequence of SEQ ID NO:4464.

[0317] Provided herein is an antibody that competes for binding to KRTAP12-3 with the antibody or antigen-binding fragment of any one of claims 792 to 795, wherein the antibody binds to human KRTAP12-3 or mouse KRTAP12-3.

[0318] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to enolase 2 (ENO2) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 734, a CDR-H2 of SEQ ID NO: 1276, and a CDR-H3 of SEQ ID NO: 1818; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 1005, a CDR-L2 of SEQ ID NO: 1547, and a CDR-L3 of SEQ ID NO: 2089. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 192, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 463. In some embodiments, the antibody or antigen-binding fragment thereof binds human ENO2, mouse ENO2, rat ENO2, bovine ENO2, or cynomolgus monkey ENO2. In some embodiments, human ENO2 comprises the sequence of SEQ ID NO:4465.

[0319] Provided herein is an antibody that competes for binding to ENO2 with the antibody or antigen-binding fragment of any one of claims 797 to 800, wherein the antibody binds to human ENO2 or mouse ENO2.

[0320] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to chromosome 11 open reading frame 68 transcript variant 1 (chromosome 11 open reading frame 68; C11orf68) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 734, a CDR-H2 of SEQ ID NO: 1276, and a CDR-H3 of SEQ ID NO: 1818; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 1005, a CDR-L2 of SEQ ID NO: 1547, and a CDR-L3 of SEQ ID NO: 2089. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 192, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 463. In some embodiments, the antibody or antigen-binding fragment thereof binds human C11orf68, mouse C11orf68, rat C11orf68, bovine C11orf68, or cynomolgus monkey C11orf68. In some embodiments, human C11orf68 comprises the sequence of SEQ ID NO:4466.

[0321] Provided herein is an antibody that competes for binding to C11orf68 with the antibody or antigen-binding fragment of any one of claims 802 to 805, wherein the antibody binds to human C11orf68 or mouse C11orf68.

[0322] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to methionyl-tRNA synthetase 1 (MARS) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 735, a CDR-H2 of SEQ ID NO: 1277, and a CDR-H3 of SEQ ID NO: 1819; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 1006, a CDR-L2 of SEQ ID NO: 1548, and a CDR-L3 of SEQ ID NO: 2090. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 193, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 464. In some embodiments, the antibody or antigen-binding fragment thereof binds human MARS, mouse MARS, rat MARS, bovine MARS or cynomolgus MARS. In some embodiments, human MARS comprises the sequence of SEQ ID NO:4467.

[0323] Provided herein is an antibody that competes for binding to MARS with the antibody or antigen-binding fragment of any one of claims 807 to 810, wherein the antibody binds to human MARS or mouse MARS.

[0324] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to serpin family B member 6 transcript variant 2 (serpin family B member 6; SERPINB6) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 737, a CDR-H2 of SEQ ID NO: 1279, and a CDR-H3 of SEQ ID NO: 1821; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 1008, a CDR-L2 of SEQ ID NO: 1550, and a CDR-L3 of SEQ ID NO: 2092. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 195, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 466. In some embodiments, the antibody or antigen-binding fragment thereof binds to human SERPINB6, mouse SERPINB6, rat SERPINB6, bovine SERPINB6, or cynomolgus monkey SERPINB6. In some embodiments, human SERPINB6 comprises the sequence of SEQ ID NO:4468.

[0325] Provided herein is an antibody that competes for binding to SERPINB6 with the antibody or antigen-binding fragment of any one of claims 812 to 815, wherein the antibody binds to human SERPINB6 or mouse SERPINB6.

[0326] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to endoplasmic reticulum protein 27 transcript variant 1 (ERP27) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 738, a CDR-H2 of SEQ ID NO: 1280, and a CDR-H3 of SEQ ID NO: 1822; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 1009, a CDR-L2 of SEQ ID NO: 1551, and a CDR-L3 of SEQ ID NO: 2093. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 196, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 467. In some embodiments, the antibody or antigen-binding fragment thereof binds human ERP27, mouse ERP27, rat ERP27, bovine ERP27, or cynomolgus monkey ERP27. In some embodiments, human ERP27 comprises the sequence of SEQ ID NO:4469.

[0327] Provided herein is an antibody that competes for binding to ERP27 with the antibody or antigen-binding fragment of any one of claims 817 to 820, wherein the antibody binds to human ERP27 or mouse ERP27.

[0328] Provided herein is an antibody or an antigen-binding fragment thereof, which selectively binds to a Dpy-30 histone methyltransferase complex regulatory subunit (DPY30) or a variant thereof, wherein the antibody or the antigen-binding fragment thereof comprises at least one of the following:

[0329] A variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 738, a CDR-H2 of SEQ ID NO: 1280, and a CDR-H3 of SEQ ID NO: 1822; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 1009, a CDR-L2 of SEQ ID NO: 1551, and a CDR-L3 of SEQ ID NO: 2093. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 196, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 467. In some embodiments, the antibody or antigen-binding fragment thereof binds to human DPY30, mouse DPY30, rat DPY30, bovine DPY30, or cynomolgus monkey DPY30. In some embodiments, human DPY30 comprises the sequence of SEQ ID NO:4470.

[0330] Provided herein is an antibody that competes for binding to DPY30 with the antibody or antigen-binding fragment of any one of claims 822 to 825, wherein the antibody binds to human DPY30 or mouse DPY30.

[0331] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to Rho GTPase binding protein-associated tail protein 1-like protein transcript variant 2 (rhophilin associated tail protein 1like; ROPN1L) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 738, a CDR-H2 of SEQ ID NO: 1280, and a CDR-H3 of SEQ ID NO: 1822; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 1009, a CDR-L2 of SEQ ID NO: 1551, and a CDR-L3 of SEQ ID NO: 2093. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 196, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 467. In some embodiments, the antibody or antigen-binding fragment thereof binds human ROPN1L, mouse ROPN1L, rat ROPN1L, bovine ROPN1L, or cynomolgus monkey ROPN1L. In some embodiments, human ROPN1L comprises the sequence of SEQ ID NO:4471.

[0332] Provided herein is an antibody that competes for binding to ROPN1L with the antibody or antigen-binding fragment of any one of claims 827 to 830, wherein the antibody binds to human ROPN1L or mouse ROPN1L.

[0333] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to endosome-associated transport regulatory factor 1 transcript variant 2 (SDCCAG3) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 739, a CDR-H2 of SEQ ID NO: 1281, and a CDR-H3 of SEQ ID NO: 1823; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 1010, a CDR-L2 of SEQ ID NO: 1552, and a CDR-L3 of SEQ ID NO: 2094. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 197, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 468. In some embodiments, the antibody or antigen-binding fragment thereof binds to human SDCCAG3, mouse SDCCAG3, rat SDCCAG3, bovine SDCCAG3 or cynomolgus monkey SDCCAG3. In some embodiments, human SDCCAG3 comprises the sequence of SEQ ID NO:4373.

[0334] Provided herein is an antibody that competes for binding to SDCCAG3 with the antibody or antigen-binding fragment of any one of claims 832 to 835, wherein the antibody binds to human SDCCAG3 or mouse SDCCAG3.

[0335] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to Jupiter microtubule-associated homolog 2 (HN1L) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 740, a CDR-H2 of SEQ ID NO: 1282, and a CDR-H3 of SEQ ID NO: 1824; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 1011, a CDR-L2 of SEQ ID NO: 1553, and a CDR-L3 of SEQ ID NO: 2095. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 198, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 469. In some embodiments, the antibody or antigen-binding fragment thereof binds human HN1L, mouse HN1L, rat HN1L, bovine HN1L, or cynomolgus monkey HN1L. In some embodiments, human HN1L comprises the sequence of SEQ ID NO:4395.

[0336] Provided herein is an antibody that competes for binding to HN1L with the antibody or antigen-binding fragment of any one of claims 837 to 840, wherein the antibody binds to human HN1L or mouse HN1L.

[0337] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to BTB domain-containing protein 8 (BTBD8) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 740, a CDR-H2 of SEQ ID NO: 1282, and a CDR-H3 of SEQ ID NO: 1824; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 1011, a CDR-L2 of SEQ ID NO: 1553, and a CDR-L3 of SEQ ID NO: 2095. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 198, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 469. In some embodiments, the antibody or antigen-binding fragment thereof binds human BTBD8, mouse BTBD8, rat BTBD8, bovine BTBD8 or cynomolgus monkey BTBD8. In some embodiments, human BTBD8 comprises the sequence of SEQ ID NO:4472.

[0338] Provided herein is an antibody that competes for binding to BTBD8 with the antibody or antigen-binding fragment of any one of claims 842 to 845, wherein the antibody binds to human BTBD8 or mouse BTBD8.

[0339] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to neutrophil cytosolic factor 4 transcript variant 2 (NCF4) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 741, a CDR-H2 of SEQ ID NO: 1283, and a CDR-H3 of SEQ ID NO: 1825; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 1012, a CDR-L2 of SEQ ID NO: 1554, and a CDR-L3 of SEQ ID NO: 2096. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 199, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 470. In some embodiments, the antibody or antigen-binding fragment thereof binds human NCF4, mouse NCF4, rat NCF4, bovine NCF4, or cynomolgus monkey NCF4. In some embodiments, human NCF4 comprises the sequence of SEQ ID NO:4473.

[0340] Provided herein is an antibody that competes for binding to NCF4 with the antibody or antigen-binding fragment of any one of claims 847 to 850, wherein the antibody binds to human NCF4 or mouse NCF4.

[0341] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to t-complex 11-like protein 2 transcript variant X2 (t-complex 11like 2; TCP11L2) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 741, a CDR-H2 of SEQ ID NO: 1283, and a CDR-H3 of SEQ ID NO: 1825; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 1012, a CDR-L2 of SEQ ID NO: 1554, and a CDR-L3 of SEQ ID NO: 2096. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 199, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 470. In some embodiments, the antibody or antigen-binding fragment thereof binds to human TCP11L2, mouse TCP11L2, rat TCP11L2, bovine TCP11L2, or cynomolgus monkey TCP11L2. In some embodiments, human TCP11L2 comprises the sequence of SEQ ID NO:4474.

[0342] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 852 to 855 for binding to TCP11L2, wherein the antibody binds to human TCP11L2 or mouse TCP11L2.

[0343] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to phospholipase C beta 2 transcript variant 4 (phospholipase C beta 2; PLCB2) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementary determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 741, a CDR-H2 of SEQ ID NO: 1283, and a CDR-H3 of SEQ ID NO: 1825; and / or

[0344] A variable light chain region, wherein the variable light chain region comprises a complementary determining region light chain 1 (CDR-L1) of SEQ ID NO: 1012, a CDR-L2 of SEQ ID NO: 1554, and a CDR-L3 of SEQ ID NO: 2096. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 199, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 470. In some embodiments, the antibody or antigen-binding fragment thereof binds to human PLCB2, mouse PLCB2, rat PLCB2, bovine PLCB2, or cynomolgus monkey PLCB2. In some embodiments, human PLCB2 comprises the sequence of SEQ ID NO: 4475.

[0345] Provided herein is an antibody that competes for binding to PLCB2 with the antibody or antigen-binding fragment of any one of claims 857 to 860, wherein the antibody binds to human PLCB2 or mouse PLCB2.

[0346] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to microtubule associated protein RP / EB family member 2 transcript variant 1 (MAPRE2) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 742, a CDR-H2 of SEQ ID NO: 1284, and a CDR-H3 of SEQ ID NO: 1826; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 1013, a CDR-L2 of SEQ ID NO: 1555, and a CDR-L3 of SEQ ID NO: 2097. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 200, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 471. In some embodiments, the antibody or antigen-binding fragment thereof binds human MAPRE2, mouse MAPRE2, rat MAPRE2, bovine MAPRE2, or cynomolgus monkey MAPRE2. In some embodiments, human MAPRE2 comprises the sequence of SEQ ID NO:4476.

[0347] Provided herein is an antibody that competes for binding to MAPRE2 with the antibody or antigen-binding fragment of any one of claims 862 to 865, wherein the antibody binds to human MAPRE2 or mouse MAPRE2.

[0348] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to DEAD box helicase 53 (DDX53) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 743, a CDR-H2 of SEQ ID NO: 1285, and a CDR-H3 of SEQ ID NO: 1827; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 1014, a CDR-L2 of SEQ ID NO: 1556, and a CDR-L3 of SEQ ID NO: 2098. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 201, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 472. In some embodiments, the antibody or antigen-binding fragment thereof binds human DDX53, mouse DDX53, rat DDX53, bovine DDX53, or cynomolgus monkey DDX53. In some embodiments, human DDX53 comprises the sequence of SEQ ID NO: 4477.

[0349] Provided herein is an antibody that competes for binding to DDX53 with the antibody or antigen-binding fragment of any one of claims 867 to 870, wherein the antibody binds to human DDX53 or mouse DDX53.

[0350] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to interleukin 27 receptor subunit alpha (IL27RA) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 744, a CDR-H2 of SEQ ID NO: 1286, and a CDR-H3 of SEQ ID NO: 1828; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 1015, a CDR-L2 of SEQ ID NO: 1557, and a CDR-L3 of SEQ ID NO: 2099. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 202, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 473. In some embodiments, the antibody or antigen-binding fragment thereof binds human IL27RA, mouse IL27RA, rat IL27RA, bovine IL27RA, or cynomolgus monkey IL27RA. In some embodiments, human IL27RA comprises the sequence of SEQ ID NO:4478.

[0351] Provided herein is an antibody that competes for binding to IL27RA with the antibody or antigen-binding fragment of any one of claims 872 to 875, wherein the antibody binds to human IL27RA or mouse IL27RA.

[0352] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to deoxyhypusine synthase (DHPS) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 745, a CDR-H2 of SEQ ID NO: 1287, and a CDR-H3 of SEQ ID NO: 1829; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 1016, a CDR-L2 of SEQ ID NO: 1558, and a CDR-L3 of SEQ ID NO: 2100. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 203, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 474. In some embodiments, the antibody or antigen-binding fragment thereof binds to human DHPS, mouse DHPS, rat DHPS, bovine DHPS or cynomolgus monkey DHPS. In some embodiments, human DHPS comprises the sequence of SEQ ID NO:4479.

[0353] Provided herein is an antibody that competes for binding to DHPS with the antibody or antigen-binding fragment of any one of claims 877 to 880, wherein the antibody binds to human DHPS or mouse DHPS.

[0354] Provided herein is an antibody or an antigen-binding fragment thereof, which selectively binds to HEAT repeat containing protein 3 transcript variant 1 (HEAT repeat containing 3; HEATR3) or a variant thereof, wherein the antibody or the antigen-binding fragment thereof comprises at least one of the following:

[0355] A variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 746, a CDR-H2 of SEQ ID NO: 1288, and a CDR-H3 of SEQ ID NO: 1830; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 1017, a CDR-L2 of SEQ ID NO: 1559, and a CDR-L3 of SEQ ID NO: 2101. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 204, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 475. In some embodiments, the antibody or antigen-binding fragment thereof binds to human HEATR3, mouse HEATR3, rat HEATR3, bovine HEATR3, or cynomolgus monkey HEATR3. In some embodiments, human HEATR3 comprises the sequence of SEQ ID NO:4480.

[0356] Provided herein is an antibody that competes for binding to HEATR3 with the antibody or antigen-binding fragment of any one of claims 882 to 885, wherein the antibody binds to human HEATR3 or mouse HEATR3.

[0357] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to DEAD box helicase 53 (DDX53) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 747, a CDR-H2 of SEQ ID NO: 1289, and a CDR-H3 of SEQ ID NO: 1831; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 1018, a CDR-L2 of SEQ ID NO: 1560, and a CDR-L3 of SEQ ID NO: 2102. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 205, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 476. In some embodiments, the antibody or antigen-binding fragment thereof binds human DDX53, mouse DDX53, rat DDX53, bovine DDX53, or cynomolgus monkey DDX53. In some embodiments, human DDX53 comprises the sequence of SEQ ID NO: 4477.

[0358] Provided herein is an antibody that competes for binding to DDX53 with the antibody or antigen-binding fragment of any one of claims 887 to 890, wherein the antibody binds to human DDX53 or mouse DDX53.

[0359] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to an adherens junction transmembrane protein Vezatin (VEZT) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 747, a CDR-H2 of SEQ ID NO: 1289, and a CDR-H3 of SEQ ID NO: 1831; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 1018, a CDR-L2 of SEQ ID NO: 1560, and a CDR-L3 of SEQ ID NO: 2102. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 205, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 476. In some embodiments, the antibody or antigen-binding fragment thereof binds human VEZT, mouse VEZT, rat VEZT, bovine VEZT, or cynomolgus monkey VEZT. In some embodiments, human VEZT comprises the sequence of SEQ ID NO:4481.

[0360] Provided herein is an antibody that competes for binding to VEZT with the antibody or antigen-binding fragment of any one of claims 892 to 895, wherein the antibody binds to human VEZT or mouse VEZT.

[0361] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to Wd repeat domain 3 (WDR3) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 747, a CDR-H2 of SEQ ID NO: 1289, and a CDR-H3 of SEQ ID NO: 1831; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 1018, a CDR-L2 of SEQ ID NO: 1560, and a CDR-L3 of SEQ ID NO: 2102. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 205, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 476. In some embodiments, the antibody or antigen-binding fragment thereof binds to human WDR3, mouse WDR3, rat WDR3, bovine WDR3 or cynomolgus monkey WDR3. In some embodiments, human WDR3 comprises the sequence of SEQ ID NO: 4482.

[0362] Provided herein is an antibody that competes for binding to WDR3 with the antibody or antigen-binding fragment of any one of claims 897 to 900, wherein the antibody binds to human WDR3 or mouse WDR3.

[0363] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to DExD / H-box helicase 58 (DExD / H-box helicase 58; DDX58) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 748, a CDR-H2 of SEQ ID NO: 1290, and a CDR-H3 of SEQ ID NO: 1832; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 1019, a CDR-L2 of SEQ ID NO: 1561, and a CDR-L3 of SEQ ID NO: 2103. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 206, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 477. In some embodiments, the antibody or antigen-binding fragment thereof binds human DDX58, mouse DDX58, rat DDX58, bovine DDX58, or cynomolgus monkey DDX58. In some embodiments, human DDX58 comprises the sequence of SEQ ID NO:4483.

[0364] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 902 to 905 for binding to DDX58, wherein the antibody binds to human DDX58 or mouse DDX58.

[0365] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to a DEXD / H-box helicase 58 (DDX58) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 748, a CDR-H2 of SEQ ID NO: 1290, and a CDR-H3 of SEQ ID NO: 1832; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 1019, a CDR-L2 of SEQ ID NO: 1561, and a CDR-L3 of SEQ ID NO: 2103. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 206, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 477. In some embodiments, the antibody or antigen-binding fragment thereof binds human DDX58, mouse DDX58, rat DDX58, bovine DDX58, or cynomolgus monkey DDX58. In some embodiments, human DDX58 comprises the sequence of SEQ ID NO:4483.

[0366] Provided herein is an antibody that competes for binding to DDX58 with the antibody or antigen-binding fragment of any one of claims 907 to 910, wherein the antibody binds to human DDX58 or mouse DDX58.

[0367] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to nudix hydrolase 22 transcript variant 2 (nudix hydrolase 22; NUDT22) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 749, a CDR-H2 of SEQ ID NO: 1291, and a CDR-H3 of SEQ ID NO: 1833; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 1020, a CDR-L2 of SEQ ID NO: 1562, and a CDR-L3 of SEQ ID NO: 2104. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 207, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 478. In some embodiments, the antibody or antigen-binding fragment thereof binds human NUDT22, mouse NUDT22, rat NUDT22, bovine NUDT22, or cynomolgus monkey NUDT22. In some embodiments, human NUDT22 comprises the sequence of SEQ ID NO:4484.

[0368] Provided herein is an antibody that competes for binding to NUDT22 with the antibody or antigen-binding fragment of any one of claims 912 to 915, wherein the antibody binds to human NUDT22 or mouse NUDT22.

[0369] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to Jupiter microtubule-associated homolog 2 (HN1L) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 750, a CDR-H2 of SEQ ID NO: 1292, and a CDR-H3 of SEQ ID NO: 1834; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 1021, a CDR-L2 of SEQ ID NO: 1563, and a CDR-L3 of SEQ ID NO: 2105. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 208, and

[0370] The variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 479. In some embodiments, the antibody or antigen-binding fragment thereof binds human HN1L, mouse HN1L, rat HN1L, bovine HN1L, or cynomolgus monkey HN1L. In some embodiments, human HN1L comprises the sequence of SEQ ID NO: 4395.

[0371] Provided herein is an antibody that competes for binding to HN1L with the antibody or antigen-binding fragment of any one of claims 917 to 920, wherein the antibody binds to human HN1L or mouse HN1L.

[0372] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to grancalcin transcript variant 4 (GCA) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 751, a CDR-H2 of SEQ ID NO: 1293, and a CDR-H3 of SEQ ID NO: 1835; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 1022, a CDR-L2 of SEQ ID NO: 1564, and a CDR-L3 of SEQ ID NO: 2106. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 209, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 480. In some embodiments, the antibody or antigen-binding fragment thereof binds to human GCA, mouse GCA, rat GCA, bovine GCA, or cynomolgus monkey GCA. In some embodiments, human GCA comprises the sequence of SEQ ID NO: 4485.

[0373] Provided herein is an antibody that competes for binding to GCA with the antibody or antigen-binding fragment of any one of claims 922 to 925, wherein the antibody binds to human GCA or mouse GCA.

[0374] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to endoplasmic reticulum protein 27 transcript variant 1 (ERP27) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 752, a CDR-H2 of SEQ ID NO: 1294, and a CDR-H3 of SEQ ID NO: 1836; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 1023, a CDR-L2 of SEQ ID NO: 1565, and a CDR-L3 of SEQ ID NO: 2107. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 210, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 481. In some embodiments, the antibody or antigen-binding fragment thereof binds human ERP27, mouse ERP27, rat ERP27, bovine ERP27, or cynomolgus monkey ERP27. In some embodiments, human ERP27 comprises the sequence of SEQ ID NO:4469.

[0375] Provided herein is an antibody that competes for binding to ERP27 with the antibody or antigen-binding fragment of any one of claims 927 to 930, wherein the antibody binds to human ERP27 or mouse ERP27.

[0376] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to RNA polymerase III subunit g (Rnapolymerase III subunit g; POLR3G) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 753, a CDR-H2 of SEQ ID NO: 1295, and a CDR-H3 of SEQ ID NO: 1837; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 1024, a CDR-L2 of SEQ ID NO: 1566, and a CDR-L3 of SEQ ID NO: 2108. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 211, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 482. In some embodiments, the antibody or antigen-binding fragment thereof binds human POLR3G, mouse POLR3G, rat POLR3G, bovine POLR3G, or cynomolgus monkey POLR3G. In some embodiments, human POLR3G comprises the sequence of SEQ ID NO:4486.

[0377] Provided herein is an antibody that competes for binding to POLR3G with the antibody or antigen-binding fragment of any one of claims 932 to 935, wherein the antibody binds to human POLR3G or mouse POLR3G.

[0378] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to sorting nexin 1 transcript variant 1 (SNX1) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 754, a CDR-H2 of SEQ ID NO: 1296, and a CDR-H3 of SEQ ID NO: 1838; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 1025, a CDR-L2 of SEQ ID NO: 1567, and a CDR-L3 of SEQ ID NO: 2109. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 212, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 483. In some embodiments, the antibody or antigen-binding fragment thereof binds human SNX1, mouse SNX1, rat SNX1, bovine SNX1, or cynomolgus monkey SNX1. In some embodiments, human SNX1 comprises the sequence of SEQ ID NO:4487.

[0379] Provided herein is an antibody that competes for binding to SNX1 with the antibody or antigen-binding fragment of any one of claims 937 to 940, wherein the antibody binds to human SNX1 or mouse SNX1.

[0380] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to SAA2-SAA3 (AB937783.1_frag) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 755, a CDR-H2 of SEQ ID NO: 1297, and a CDR-H3 of SEQ ID NO: 1839; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 1026, a CDR-L2 of SEQ ID NO: 1568, and a CDR-L3 of SEQ ID NO: 2110. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 213, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 484. In some embodiments, the antibody or antigen-binding fragment thereof binds human AB937783.1_frag, mouse AB937783.1_frag, rat AB937783.1_frag, bovine AB937783.1_frag or cynomolgus monkey AB937783.1_frag. In some embodiments, human AB937783.1_frag comprises the sequence of SEQ ID NO:4488.

[0381] Provided herein is an antibody that competes for binding to AB937783.1_frag with the antibody or antigen-binding fragment of any one of claims 942 to 945, wherein the antibody binds to human AB937783.1_frag or mouse AB937783.1_frag.

[0382] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to proteasome 26S subunit, non-ATPase 3 (PSMD3) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 755, a CDR-H2 of SEQ ID NO: 1297, and a CDR-H3 of SEQ ID NO: 1839; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 1026, a CDR-L2 of SEQ ID NO: 1568, and a CDR-L3 of SEQ ID NO: 2110. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 213, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 484. In some embodiments, the antibody or antigen-binding fragment thereof binds to human PSMD3, mouse PSMD3, rat PSMD3, bovine PSMD3 or cynomolgus monkey PSMD3. In some embodiments, human PSMD3 comprises the sequence of SEQ ID NO:4489.

[0383] Provided herein is an antibody that competes for binding to PSMD3 with the antibody or antigen-binding fragment of any one of claims 947 to 950, wherein the antibody binds to human PSMD3 or mouse PSMD3.

[0384] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to CRK like proto-oncogene, adaptor protein transcript variant 1 (CRK like proto-oncogene, adaptor protein; CRKL) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 756, a CDR-H2 of SEQ ID NO: 1298, and a CDR-H3 of SEQ ID NO: 1840; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 1027, a CDR-L2 of SEQ ID NO: 1569, and a CDR-L3 of SEQ ID NO: 2111. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 214, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 485. In some embodiments, the antibody or antigen-binding fragment thereof binds to human CRKL, mouse CRKL, rat CRKL, bovine CRKL or cynomolgus monkey CRKL. In some embodiments, human CRKL comprises the sequence of SEQ ID NO:4490.

[0385] Provided herein is an antibody that competes for binding to CRKL with the antibody or antigen-binding fragment of any one of claims 952 to 955, wherein the antibody binds to human CRKL or mouse CRKL.

[0386] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to F-box protein 2 (FBXO2) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 757, a CDR-H2 of SEQ ID NO: 1299, and a CDR-H3 of SEQ ID NO: 1841; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 1028, a CDR-L2 of SEQ ID NO: 1570, and a CDR-L3 of SEQ ID NO: 2112. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 215, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 486. In some embodiments, the antibody or antigen-binding fragment thereof binds human FBXO2, mouse FBXO2, rat FBXO2, bovine FBXO2, or cynomolgus monkey FBXO2. In some embodiments, human FBXO2 comprises the sequence of SEQ ID NO:4491.

[0387] Provided herein is an antibody that competes for binding to FBXO2 with the antibody or antigen-binding fragment of any one of claims 957 to 960, wherein the antibody binds to human FBXO2 or mouse FBXO2.

[0388] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to tubulin gamma 1 (TUBG1) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 757, a CDR-H2 of SEQ ID NO: 1299, and a CDR-H3 of SEQ ID NO: 1841; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 1028, a CDR-L2 of SEQ ID NO: 1570, and a CDR-L3 of SEQ ID NO: 2112. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 215, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 486. In some embodiments, the antibody or antigen-binding fragment thereof binds human TUBG1, mouse TUBG1, rat TUBG1, bovine TUBG1, or cynomolgus monkey TUBG1. In some embodiments, human TUBG1 comprises the sequence of SEQ ID NO:4492.

[0389] Provided herein is an antibody that competes for binding to TUBG1 with the antibody or antigen-binding fragment of any one of claims 962 to 965, wherein the antibody binds to human TUBG1 or mouse TUBG1.

[0390] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to antioxidant protein 1 transcript variant 1 (oxidation resistance 1; OXR1) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 759, a CDR-H2 of SEQ ID NO: 1301, and a CDR-H3 of SEQ ID NO: 1843; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 1030, a CDR-L2 of SEQ ID NO: 1572, and a CDR-L3 of SEQ ID NO: 2114. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 217, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 488. In some embodiments, the antibody or antigen-binding fragment thereof binds human OXR1, mouse OXR1, rat OXR1, bovine OXR1, or cynomolgus monkey OXR1. In some embodiments, wherein human OXR1 comprises the sequence of SEQ ID NO:4493.

[0391] Provided herein is an antibody that competes for binding to OXR1 with the antibody or antigen-binding fragment of any one of claims 967 to 970, wherein the antibody binds to human OXR1 or mouse OXR1.

[0392] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to ankyrin repeat domain 20 family member a5 pseudogene (ANKRD20A5P) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 760, a CDR-H2 of SEQ ID NO: 1302, and a CDR-H3 of SEQ ID NO: 1844; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 1031, a CDR-L2 of SEQ ID NO: 1573, and a CDR-L3 of SEQ ID NO: 2115. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 218, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 489. In some embodiments, the antibody or antigen-binding fragment thereof binds human ANKRD20A5P, mouse ANKRD20A5P, rat ANKRD20A5P, bovine ANKRD20A5P or cynomolgus monkey ANKRD20A5P. In some embodiments, human ANKRD20A5P comprises the sequence of SEQ ID NO:4494.

[0393] Provided herein is an antibody that competes for binding to ANKRD20A5P with the antibody or antigen-binding fragment of any one of claims 972 to 975, wherein the antibody binds to human ANKRD20A5P or mouse ANKRD20A5P.

[0394] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to Kirre like nephrin family adhesion molecule 1 (KIRREL) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 760, a CDR-H2 of SEQ ID NO: 1302, and a CDR-H3 of SEQ ID NO: 1844; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 1031, a CDR-L2 of SEQ ID NO: 1573, and a CDR-L3 of SEQ ID NO: 2115. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 218, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 489. In some embodiments, the antibody or antigen-binding fragment thereof binds human KIRREL, mouse KIRREL, rat KIRREL, bovine KIRREL, or cynomolgus monkey KIRREL. In some embodiments, human KIRREL comprises the sequence of SEQ ID NO:4495.

[0395] Provided herein is an antibody that competes for binding to KIRREL with the antibody or antigen-binding fragment of any one of claims 977 to 980, wherein the antibody binds to human KIRREL or mouse KIRREL.

[0396] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to GRB10 interacting GYF protein 1 transcript variant X10 (GRB10 interacting GYF protein 1; GIGYF1) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 760, a CDR-H2 of SEQ ID NO: 1302, and a CDR-H3 of SEQ ID NO: 1844; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 1031, a CDR-L2 of SEQ ID NO: 1573, and a CDR-L3 of SEQ ID NO: 2115. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 218, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 489. In some embodiments, the antibody or antigen-binding fragment thereof binds human GIGYF1, mouse GIGYF1, rat GIGYF1, bovine GIGYF1, or cynomolgus monkey GIGYF1. In some embodiments, human GIGYF1 comprises the sequence of SEQ ID NO:4496.

[0397] Provided herein is an antibody that competes for binding to GIGYF1 with the antibody or antigen-binding fragment of any one of claims 982 to 985, wherein the antibody binds to human GIGYF1 or mouse GIGYF1.

[0398] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to defensin alpha 3 (DEFA3) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 761, a CDR-H2 of SEQ ID NO: 1303, and a CDR-H3 of SEQ ID NO: 1845; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 1032, a CDR-L2 of SEQ ID NO: 1574, and a CDR-L3 of SEQ ID NO: 2116. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 219, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 490. In some embodiments, the antibody or antigen-binding fragment thereof binds human DEFA3, mouse DEFA3, rat DEFA3, bovine DEFA3, or cynomolgus monkey DEFA3. In some embodiments, human DEFA3 comprises the sequence of SEQ ID NO:4497.

[0399] Provided herein is an antibody that competes for binding to DEFA3 with the antibody or antigen-binding fragment of any one of claims 987 to 990, wherein the antibody binds to human DEFA3 or mouse DEFA3.

[0400] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to radial spoke head 14 homolog (RSPH14) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 762, a CDR-H2 of SEQ ID NO: 1304, and a CDR-H3 of SEQ ID NO: 1846; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 1033, a CDR-L2 of SEQ ID NO: 1575, and a CDR-L3 of SEQ ID NO: 2117. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 220, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 491. In some embodiments, the antibody or antigen-binding fragment thereof binds human RSPH14, mouse RSPH14, rat RSPH14, bovine RSPH14, or cynomolgus monkey RSPH14. In some embodiments, human RSPH14 comprises the sequence of SEQ ID NO:4498.

[0401] Provided herein is an antibody that competes for binding to RSPH14 with the antibody or antigen-binding fragment of any one of claims 992 to 995, wherein the antibody binds to human RSPH14 or mouse RSPH14.

[0402] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to C-C motif chemokine ligand 2 (CCL2) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 763, a CDR-H2 of SEQ ID NO: 1305, and a CDR-H3 of SEQ ID NO: 1847; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 1034, a CDR-L2 of SEQ ID NO: 1576, and a CDR-L3 of SEQ ID NO: 2118. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 221, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 492. In some embodiments, the antibody or antigen-binding fragment thereof binds human CCL2, mouse CCL2, rat CCL2, bovine CCL2, or cynomolgus monkey CCL2. In some embodiments, human CCL2 comprises the sequence of SEQ ID NO:4499.

[0403] Provided herein is an antibody that competes for binding to CCL2 with the antibody or antigen-binding fragment of any one of claims 997 to 1000, wherein the antibody binds to human CCL2 or mouse CCL2.

[0404] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to killer cell lectin-like receptor C1 transcript variant 3 (KLRC1) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 764, a CDR-H2 of SEQ ID NO: 1306, and a CDR-H3 of SEQ ID NO: 1848; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 1035, a CDR-L2 of SEQ ID NO: 1577, and a CDR-L3 of SEQ ID NO: 2119. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 222, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 493. In some embodiments, the antibody or antigen-binding fragment thereof binds human KLRC1, mouse KLRC1, rat KLRC1, bovine KLRC1, or cynomolgus monkey KLRC1. In some embodiments, human KLRC1 comprises the sequence of SEQ ID NO:4500.

[0405] Provided herein is an antibody that competes for binding to KLRC1 with the antibody or antigen-binding fragment of any one of claims 1002 to 1005, wherein the antibody binds to human KLRC1 or mouse KLRC1.

[0406] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to kelch-like family member 12 transcript variant 2 (KLHL12) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 764, a CDR-H2 of SEQ ID NO: 1306, and a CDR-H3 of SEQ ID NO: 1848; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 1035, a CDR-L2 of SEQ ID NO: 1577, and a CDR-L3 of SEQ ID NO: 2119. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 222, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 493. In some embodiments, the antibody or antigen-binding fragment thereof binds human KLHL12, mouse KLHL12, rat KLHL12, bovine KLHL12, or cynomolgus monkey KLHL12. In some embodiments, human KLHL12 comprises the sequence of SEQ ID NO: 4501.

[0407] Provided herein is an antibody that competes for binding to KLHL12 with the antibody or antigen-binding fragment of any one of claims 1007 to 1010, wherein the antibody binds to human KLHL12 or mouse KLHL12.

[0408] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to neural retina leucine zipper transcript variant X4 (NRL) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 765, a CDR-H2 of SEQ ID NO: 1307, and a CDR-H3 of SEQ ID NO: 1849; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 1036, a CDR-L2 of SEQ ID NO: 1578, and a CDR-L3 of SEQ ID NO: 2120. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 223, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 494. In some embodiments, the antibody or antigen-binding fragment thereof binds to human NRL, mouse NRL, rat NRL, bovine NRL, or cynomolgus monkey NRL. In some embodiments, human NRL comprises the sequence of SEQ ID NO: 4502.

[0409] Provided herein is an antibody that competes for binding to NRL with the antibody or antigen-binding fragment of any one of claims 1012 to 1015, wherein the antibody binds to human NRL or mouse NRL.

[0410] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to phospholipase C delta 4 (PLCD4) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of the following: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 766, a CDR-H2 of SEQ ID NO: 1308, and a CDR-H3 of SEQ ID NO: 1850; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 1037, a CDR-L2 of SEQ ID NO: 1579, and a CDR-L3 of SEQ ID NO: 2121. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 224, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 495. In some embodiments, the antibody or antigen-binding fragment thereof binds human PLCD4, mouse PLCD4, rat PLCD4, bovine PLCD4 or cynomolgus monkey PLCD4. In some embodiments, human PLCD4 comprises the sequence of SEQ ID NO:4503.

[0411] Provided herein is an antibody that competes for binding to PLCD4 with the antibody or antigen-binding fragment of any one of claims 1017 to 1020, wherein the antibody binds to human PLCD4 or mouse PLCD4.

[0412] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to coiled-coil domain-containing protein 74B transcript variant 2 (CCDC74B) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 767, a CDR-H2 of SEQ ID NO: 1309, and a CDR-H3 of SEQ ID NO: 1851; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 1038, a CDR-L2 of SEQ ID NO: 1580, and a CDR-L3 of SEQ ID NO: 2122. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 225, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 496. In some embodiments, the antibody or antigen-binding fragment thereof binds human CCDC74B, mouse CCDC74B, rat CCDC74B, bovine CCDC74B, or cynomolgus monkey CCDC74B. In some embodiments, human CCDC74B comprises the sequence of SEQ ID NO:4504.

[0413] Provided herein is an antibody that competes for binding to CCDC74B with the antibody or antigen-binding fragment of any one of claims 1022 to 1025, wherein the antibody binds to human CCDC74B or mouse CCDC74B.

[0414] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to DEAD box helicase 53 (DDX53) or a variant thereof, the antibody or antigen-binding fragment thereof comprising at least one of: a variable heavy chain region, wherein the variable heavy chain region comprises a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 768, a CDR-H2 of SEQ ID NO: 1310, and a CDR-H3 of SEQ ID NO: 1852; and / or a variable light chain region, wherein the variable light chain region comprises a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 1039, a CDR-L2 of SEQ ID NO: 1581, and a CDR-L3 of SEQ ID NO: 2123. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 226, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid s...

Claims

1. An antibody or antigen-binding fragment thereof that specifically binds to G antigen 2A, comprising: (a) complementarity determining region 1 (CDR-H1), CDR-H2 and CDR-H3 of the heavy chain variable region, wherein: (i) the sequence of CDR-H1 is SEQ ID NO: 794, (ii) the sequence of CDR-H2 is SEQ ID NO: 1336, and (iii) the sequence of CDR-H3 is SEQ ID NO: 1878; and (b) complementarity determining region 1 (CDR-L1), CDR-L2 and CDR-L3 of the light chain variable region, wherein: (i) the sequence of CDR-L1 is SEQ ID NO: 1065, (ii) the sequence of CDR-L2 is SEQ ID NO: 1607, and (iii) The sequence of CDR-L3 is SEQ ID NO:2149.

2. The antibody or antigen-binding fragment thereof according to claim 1, comprising: (a) a heavy chain variable region, wherein the heavy chain variable region comprises a sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 252; and (b) a light chain variable region, wherein the light chain variable region comprises a sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:

523.

3. The antibody or antigen-binding fragment thereof according to any one of claims 1 to 2, wherein the antibody comprises a humanized antibody, a human antibody, a monoclonal antibody, a multivalent antibody or a combination thereof.

4. The antibody or antigen-binding fragment thereof according to any one of claims 1 to 2, wherein the antigen-binding fragment comprises Fab, Fab', Fab'-SH, Fv, scFv or F(ab')2.

5. A pharmaceutical composition comprising the antibody or antigen-binding fragment thereof according to any one of claims 1 to 4, and a pharmaceutically acceptable carrier, excipient or diluent.

6. An isolated nucleic acid molecule encoding an antibody or antigen-binding fragment thereof that specifically binds to G antigen 2A, the antibody or antigen-binding fragment thereof comprising: The complementarity determining region 1 (CDR-H1), CDR-H2 and CDR-H3 of the heavy chain variable region, wherein: (i) the sequence of CDR-H1 is SEQ ID NO: 794, (ii) the sequence of CDR-H2 is SEQ ID NO: 1336, and (iii) the sequence of CDR-H3 is SEQ ID NO: 1878; and The complementarity determining region 1 (CDR-L1), CDR-L2 and CDR-L3 of the light chain variable region, wherein: (i) the sequence of CDR-L1 is SEQ ID NO: 1065, (ii) the sequence of CDR-L2 is SEQ ID NO: 1607, and (iii) The sequence of CDR-L3 is SEQ ID NO:2149.

7. A vector comprising the isolated nucleic acid molecule according to claim 6.

8. The vector of claim 7, wherein the isolated nucleic acid is operably linked to a regulatory sequence.

9. A host cell comprising the vector according to claim 7 or 8 or the isolated nucleic acid molecule according to claim 6.

10. A method for producing an antibody or an antigen-binding fragment thereof, the method comprising: (a) culturing the host cell according to claim 9 in a culture medium under conditions that allow expression of the polypeptide encoded by the isolated nucleic acid molecule and assembly of the antibody or antigen-binding fragment thereof; and (b) purifying the antibody or antigen-binding fragment thereof from the cultured cells or the cell culture medium.

Images